<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Etoposide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Etoposide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Etoposide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12458" href="/d/html/12458.html" rel="external">see "Etoposide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13292" href="/d/html/13292.html" rel="external">see "Etoposide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708769"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Etoposide should be administered under the supervision of a qualified health care provider experienced in the use of cancer chemotherapeutic agents.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Severe myelosuppression, with resulting infection or bleeding, may occur.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F169278"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Toposar [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866853"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>GEN-Etoposide;</li>
<li>VePesid</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F169333"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Podophyllotoxin Derivative;</li>
<li>
                        Antineoplastic Agent, Topoisomerase II Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F169283"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="325fe1c9-065e-450c-9429-246476af14bd">Acute lymphoblastic leukemia, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, relapsed/refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 mg/m<sup>2</sup> on days 1 to 5 (in combination with mitoxantrone, ifosfamide, and mesna) as induction therapy; if complete remission occurred following induction, one additional cycle as consolidation therapy was administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8352235']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8352235'])">Ref</a></span>) <b>or</b> (adults &lt;20 years of age) 100 mg/m<sup>2</sup> on days 1 to 5 (in combination with clofarabine and cyclophosphamide) as induction (a second 5-day induction cycle may be administered if a partial response occurred), followed by 100 mg/m<sup>2</sup> on days 1 to 4 (in combination with clofarabine and cyclophosphamide) as consolidation; a total of up to 4 cycles (induction and consolidation) may be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22303898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22303898'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="498858a4-7922-47cd-86ca-32108f3e893f">Acute myeloid leukemia, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 80 mg/m<sup>2</sup> on days 1 to 6 (in combination with mitoxantrone and cytarabine); if complete remission occurred following induction, an additional cycle of 80 mg/m<sup>2</sup> on days 1 to 4 (in combination with mitoxantrone and cytarabine) as consolidation was administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2045861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2045861'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> on days 1 to 5 (in combination with mitoxantrone); if complete remission occurred following induction, an additional cycle of 75 mg/m<sup>2</sup> on days 1 to 5 (in combination with mitoxantrone and cytarabine) as consolidation was administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3422260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3422260'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bdf93c9f-b469-4ebb-a761-64ccd7863dae">Adrenocortical carcinoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenocortical carcinoma, advanced (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 mg/m<sup>2</sup> on days 2, 3, and 4 every 4 weeks (in combination with doxorubicin, cisplatin, and mitotane) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22551107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22551107'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> on days 5, 6, and 7 every 4 weeks (in combination with doxorubicin, cisplatin, and mitotane) until disease progression or unacceptable toxicity up to a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16172198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16172198'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="105cec0a-a7ca-40e2-861c-ca22d0bd524f">AIDS-related Kaposi sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>AIDS-related Kaposi sarcoma (off-label use; based on limited data):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 mg/m<sup>2</sup> every 8 hours for 7 consecutive days every 21 days until persistent toxicity or a therapy delay beyond day 28 occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11319295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11319295'])">Ref</a></span>) <b>or</b> 50 mg (flat dose) once daily for 7 consecutive days every 14 days; after 2 cycles, in patients without a response (complete or partial), may escalate the dose to 100 mg (flat dose) once daily for 7 consecutive days every 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12149296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12149296'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7a48119-602f-4b7c-998e-057aaa6bb0ea">Brain metastases, due to breast or non-small cell lung cancers</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brain metastases, due to breast or non-small cell lung cancers (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 mg/m<sup>2</sup> on days 1, 3, and 5 (or on days 4, 6, and 8) every 3 weeks (in combination with cisplatin) for up to 6 cycles in the absence of disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10193952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10193952'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intrathecal/Intraventricular (off-</b>
<b>label route; based on limited data): </b>1 mg via Ommaya reservoir once weekly until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26258900','lexi-content-ref-25879815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26258900','lexi-content-ref-25879815'])">Ref</a></span>) <b>or</b> 0.5 mg via Ommaya reservoir once daily for 5 consecutive days per week every other week for a total of 8 weeks (20 total doses), followed by maintenance intrathecal therapy of 0.5 mg via Ommaya reservoir once daily for 5 consecutive days every 4 weeks; continue until disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16583432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16583432'])">Ref</a></span>) <b>or </b>0.5 mg via Ommaya or Rickham reservoir once daily for 5 consecutive days every 2 to 5 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11384092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11384092'])">Ref</a></span>). Refer to articles for further information. <b>Note:</b> Preservative-free etoposide formulations should be utilized.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8423721-7a23-4fed-bf36-91a0c75f98e6">Breast cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 50 mg/m<sup>2</sup> once daily for 21 days of a 28-day cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8164052','lexi-content-ref-10857889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8164052','lexi-content-ref-10857889'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49fe01c0-c897-41b4-a63d-329062417bc6">Gestational trophoblastic neoplasia, high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gestational trophoblastic neoplasia, high-risk (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>EMA-CO regimen:</i>
<b>IV: </b>100 mg/m<sup>2</sup> on days 1 and 2 every 2 weeks (in combination with methotrexate, leucovorin, dactinomycin, cyclophosphamide, and vincristine); continue for at least 2 treatment cycles after a normal hCG level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14675675','lexi-content-ref-17086804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14675675','lexi-content-ref-17086804'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>EMA-EP regimen:</i>
<b>IV: </b>100 mg/m<sup>2</sup> on days 1, 2, and 8 every 2 weeks (in combination with methotrexate, leucovorin, dactinomycin, and cisplatin) for 2 to 4 treatment cycles after a normal hCG level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15086738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15086738'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>EP-EMA regimen:</i> EP: <b>IV: </b>150 mg/m<sup>2</sup> on day 1 (followed by cisplatin) alternating weekly with EMA: 100 mg/m<sup>2</sup> on day 1 (in combination with methotrexate, leucovorin, and dactinomycin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10673528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10673528'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BEP regimen (for refractory disease</i>
<i>):</i>
<b>IV:</b> 100 mg/m<sup>2</sup> on days 1 to 4 every 3 weeks (in combination with bleomycin, cisplatin, and WBC growth factor support) for at least 2 treatment cycles after a normal hCG level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15863169','lexi-content-ref-20626175','lexi-content-ref-22696816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15863169','lexi-content-ref-20626175','lexi-content-ref-22696816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ICE regimen (for refractory disease; based on limited data):</i>
<b>IV: </b>75 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 weeks (in combination with ifosfamide, mesna, and carboplatin) for at least 2 treatment cycles after a normal hCG level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15863169','lexi-content-ref-20626175','lexi-content-ref-22696816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15863169','lexi-content-ref-20626175','lexi-content-ref-22696816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TP/TE regimen (for refractory disease):</i>
<b>IV: </b>150 mg/m<sup>2</sup> on day 15 of a 28-day cycle (TE; in combination with paclitaxel) alternating every 2 weeks with TP (paclitaxel and cisplatin); continue until hCG level is normal for at least 8 weeks, or until treatment resistance (plateaued or rising hCG) or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18453518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18453518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Low-dose EP induction regimen (consider prior to EMA/CO in patients with high tumor burden):</i>
<b>IV: </b>100 mg/m<sup>2</sup> on days 1 and 2 every week (in combination with cisplatin) for 1 to 2 cycles, followed by the EMA-CO regimen until hCG levels normalize and then for a further 6 to 8 weeks; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23233709']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23233709'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41fcb3a2-3718-46cb-a41a-e5838d6fd66e">Hematopoietic stem cell transplant conditioning regimen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplant conditioning regimen (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> once daily for 4 days on days −5, −4, −3, and −2 prior to autologous transplant (in combination with carmustine, cytarabine, and melphalan [BEAM regimen]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8443375','lexi-content-ref-7884420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8443375','lexi-content-ref-7884420'])">Ref</a></span>) <b>or</b> 60 mg/kg as a single dose on day −4 prior to autologous transplant (in combination with cyclophosphamide and total body irradiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7989928','lexi-content-ref-7989929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7989928','lexi-content-ref-7989929'])">Ref</a></span>) <b>or</b> 60 mg/kg as a single dose on day −3 prior to allogeneic transplant (in combination with total body irradiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8219241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8219241'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f86a6d7e-6c6e-408e-a183-ae5d2b796973">Hemophagocytic lymphohistiocytosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophagocytic lymphohistiocytosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HLH-94 protocol:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Initial therapy: <b>IV: </b>150 mg/m<sup>2</sup> twice weekly for 2 weeks, then 150 mg/m<sup>2</sup> once weekly for 6 weeks (in combination with dexamethasone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9121398','lexi-content-ref-12239144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9121398','lexi-content-ref-12239144'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuation therapy (depending on clinical factors; refer to protocol for details): <b>IV: </b>150 mg/m<sup>2</sup> once every 2 weeks (in combination with dexamethasone pulses, cyclosporine, and intrathecal methotrexate) until hematopoietic stem cell transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9121398','lexi-content-ref-12239144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9121398','lexi-content-ref-12239144'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Consider reducing the etoposide frequency from twice weekly to once weekly and/or a dose reduction from 150 mg/m<sup>2</sup>/dose to 50 to 100 mg/m<sup>2</sup>/dose in adults with comorbidities or organ dysfunction; in patients with hemophagocytic lymphohistiocytosis without malignancy, a maximum cumulative etoposide dose of 2 to 3 g/m<sup>2</sup> should not be exceeded (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30992265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30992265'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BEACOPP (escalated) regimen:</i>
<b>IV: </b>200 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 weeks (in combination with bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) for 4 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12802024','lexi-content-ref-19704068','lexi-content-ref-12078889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12802024','lexi-content-ref-19704068','lexi-content-ref-12078889'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Stanford V regimen:</i>
<b>IV: </b>60 mg/m<sup>2</sup> on days 1 and 2 of weeks 3, 7, and 11 of a 12-week cycle (in combination with mechlorethamine, vinblastine, vincristine, bleomycin, doxorubicin, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11821442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11821442'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fb14b36-2d15-4937-a206-ae801728e441">Merkel cell carcinoma, high risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Merkel cell carcinoma, high risk (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 80 mg/m<sup>2</sup> on days 1 to 3 (in combination with carboplatin) during weeks 1 and 4 of concurrent synchronous radiation therapy and then 80 mg/m<sup>2</sup> on days 1 to 3 during weeks 7 and 10 (in combination with carboplatin) (or every 28 days if blood counts not recovered) for a total of 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14645427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14645427'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4f575b1-9ab5-4ea5-b16e-1724f4fcbc62">Multiple myeloma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DT-PACE regimen:</i>
<b>IV: </b>40 mg/m<sup>2</sup>/day administered as a continuous infusion on days 1 to 4 of each cycle; repeat every 4 to 6 weeks (in combination with dexamethasone, thalidomide, cisplatin, doxorubicin, and cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12860952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12860952'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VDT-PACE regimen:</i>
<b>IV: </b>40 mg/m<sup>2</sup>/day administered as a continuous infusion on days 1 to 4 of each cycle; repeat every 4 to 6 weeks (in combination with bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, and cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12860952','lexi-content-ref-18302711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12860952','lexi-content-ref-18302711'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9372c6c2-66a3-4c31-a0f2-09b29d882572">Neuroendocrine tumors, metastatic carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroendocrine tumors, metastatic carcinoma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 mg/m<sup>2</sup> on days 1, 2, and 3 every 4 weeks (in combination with cisplatin; refer to protocol for infusion information) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11571721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11571721'])">Ref</a></span>) <b>or</b> 130 mg/m<sup>2</sup> as a continuous infusion on days 1, 2, and 3 every 4 weeks (in combination with cisplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1712661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1712661'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 weeks (in combination with cisplatin) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23406729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23406729'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Diffuse large B-cell lymphoma:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dose-adjusted EPOCH-R regimen:</i>
<b>IV:</b> Initial: 50 mg/m<sup>2</sup>/day continuous infusion for 4 days (over 96 hours) (total 200 mg/m<sup>2</sup>/cycle) of a 21-day treatment cycle (in combination with prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) for 6 to 8 cycles; dose-adjusted for subsequent cycles based on neutrophil and platelet counts during nadir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17233819','lexi-content-ref-11929754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17233819','lexi-content-ref-11929754'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>R-CEOP regimen:</i>
<b>IV, Oral:</b> 50 mg/m<sup>2</sup> IV on day 1, followed by 100 mg/m<sup>2</sup> orally on days 2 and 3 of a 21-day treatment cycle for 3 to 6 cycles (in combination with rituximab, cyclophosphamide, vincristine, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22276299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22276299'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>R-ICE regimen:</i>
<b>IV:</b> 100 mg/m<sup>2</sup> on days 3, 4, and 5 (in combination with rituximab, ifosfamide, mesna, and carboplatin) every 2 weeks for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14739217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14739217'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Peripheral T-cell lymphoma:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CHOEP regimen:</i>
<b>IV:</b> 100 mg/m<sup>2</sup> on days 1, 2, and 3 of a 21-day treatment cycle (in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone) for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14982884','lexi-content-ref-20660290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14982884','lexi-content-ref-20660290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Primary mediastinal B-cell lymphoma:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>DA-EPOCH-R regimen:</i> Initial: <b>IV:</b> 50 mg/m<sup>2</sup>/day as a continuous infusion on days 1 to 4 (over 96 hours) dose-adjusted for subsequent cycles based on neutrophil and platelet counts during nadir (in combination with vincristine, prednisone, cyclophosphamide, doxorubicin, rituximab, and filgrastim); repeat cycle every 3 weeks for a total of 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23574119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23574119'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Other non-Hodgkin lymphoma regimens:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CEPP(B) regimen:</i> Initial: <b>IV: </b>70 mg/m<sup>2</sup> on days 1, 2, and 3; may increase dose with subsequent cycles (refer to protocol for details) every 28 days (in combination with cyclophosphamide, procarbazine, prednisone, ± bleomycin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2207307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2207307'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>ESHAP regimen:</i>
<b>IV:</b> 40 mg/m<sup>2</sup> on days 1 to 4 (in combination with methylprednisolone, cisplatin, and cytarabine) every 3 to 4 weeks for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8201379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8201379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>PEP-C regimen:</i>
<b>Oral:</b> 50 mg (flat dose) once daily after dinner (length of induction cycle depends on blood counts; frequency may vary based on tolerance in maintenance cycle; in combination with prednisone, procarbazine, and cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18338745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18338745'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c818fdd2-0859-4362-9aae-976c7de99cda">Non–small cell lung cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 mg/m<sup>2</sup> days 1, 2, and 3 every 3 weeks for 4 cycles or every 4 weeks for 3 to 4 cycles (in combination with cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14736927']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14736927'])">Ref</a></span>) <b>or</b> 50 mg/m<sup>2</sup> days 1 to 5 and days 29 to 33 (in combination with cisplatin and radiation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19632716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19632716'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f7eb7e5-238e-446f-97d8-9a1180cfd4ea">Ovarian cancer, epithelial, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, epithelial, refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 50 mg/m<sup>2</sup> once daily for 21 days every 4 weeks until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9469322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9469322'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e1bdba6-0de7-42e9-b2e3-f19a8abfb16a">Ovarian germ cell tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian germ cell tumors (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BEP regimen:</i>
<b>IV: </b>100 mg/m<sup>2</sup> on days 1 to 5 every 21 days (in combination with bleomycin and cisplatin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7512129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7512129'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>EP regimen:</i>
<b>IV: </b>100 mg/m<sup>2</sup> on days 1 to 5 every 21 days (in combination with cisplatin) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17351252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17351252'])">Ref</a></span>); while the BEP regimen is preferred in the treatment of ovarian germ cell tumors, EP may be considered if pulmonary toxicity is a concern. <b>Note:</b> Use of this regimen in ovarian germ cell tumors is extrapolated from data in the management of testicular germ cell tumors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Carboplatin/etoposide regimen:</i>
<b>IV: </b>120 mg/m<sup>2</sup> days 1, 2, and 3 every 4 weeks (in combination with carboplatin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15581952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15581952'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a0d01f-7598-4295-91fc-098cdd1ce6dd">Prostate cancer, metastatic, castration resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration resistant (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> 120 mg/m<sup>2</sup> IV on days 1, 2, and 3 every 3 weeks (in combination with cisplatin, as second-line treatment following first-line treatment with carboplatin and docetaxel) for at least 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23649003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23649003'])">Ref</a></span>) <b>or</b> 80 mg/m<sup>2</sup> IV on day 1, followed by 80 mg/m<sup>2</sup> orally on days 2 and 3 (in combination with carboplatin) every 3 weeks until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19179557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19179557'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c1a5c70e-298f-4f06-887a-e8996574877a">Sarcomas, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sarcomas, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adults &lt;22 years of age: <b>IV: </b>100 mg/m<sup>2</sup>/day on days 1 to 5 every 3 weeks (in combination with ifosfamide, mesna, and carboplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15503297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15503297'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="458043c8-a34c-4eaf-b646-6c3a69473044">Small cell lung cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer (combination chemotherapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Limited-stage disease (off-label dosing/combinations):</i></b>
<b>IV:</b> 120 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 weeks (in combination with cisplatin and concurrent radiation) for 4 courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9920950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9920950'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> on days 1, 2, and 3 every 4 weeks (in combination with cisplatin and concurrent radiation) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12118018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12118018'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 weeks (in combination with cisplatin and sequential radiation) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12118018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12118018'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 weeks (in combination with carboplatin and radiation) up to a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11697833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11697833'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> IV on day 1 (in combination with cisplatin and concurrent radiation), followed by 200 mg/m<sup>2</sup>
<b>orally</b> on days 2 through 4 every 3 weeks for a maximum of 5 courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12488411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12488411'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 to 4 weeks (in combination with cisplatin) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2997406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2997406'])">Ref</a></span>). According to American Society of Clinical Oncology (ASCO) guidelines, platinum-based therapy (cisplatin or carboplatin) in combination with either etoposide or irinotecan for 4 cycles is recommended over other regimens for limited-stage disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26351333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26351333'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Extensive-stage disease (off-label dosing/combinations):</i></b>
<b>IV:</b> 100 mg/m<sup>2</sup> IV on days 1, 2, and 3 every 3 weeks (in combination with carboplatin and atezolizumab) for 4 induction cycles, followed by atezolizumab maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30280641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30280641'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> IV on days 1, 2, and 3 every 3 weeks (in combination with cisplatin) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19349543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19349543'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> IV on day 1 (in combination with cisplatin and concurrent radiation), followed by 200 mg/m<sup>2</sup>
<b>orally</b> on days 2 through 4 every 3 weeks for a maximum of 5 courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12488411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12488411'])">Ref</a></span>) <b>or</b> 80 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 weeks (in combination with cisplatin) up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7931470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7931470'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 weeks (in combination with carboplatin) up to a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19720897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19720897'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 to 4 weeks (in combination with cisplatin) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2997406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2997406'])">Ref</a></span>). According to ASCO guidelines, platinum-based therapy (cisplatin or carboplatin) in combination with either etoposide or irinotecan for 4 to 6 cycles is recommended over other regimens for extensive-stage disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26351333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26351333'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>IV to oral conversion:</i></b> Due to poor bioavailability, oral doses should be twice the IV dose (and rounded to the nearest 50 mg) according to the manufacturer.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="982f4303-339c-4c1a-99c3-5e173bacf459">Soft tissue sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcoma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>EIA regimen:</i>
<b>IV:</b> 125 mg/m<sup>2</sup> on days 1 and 4 (in combination with ifosfamide, doxorubicin, and regional hyperthermia) every 3 weeks until progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20434400','lexi-content-ref-29450452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20434400','lexi-content-ref-29450452'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0072c46f-e6af-4b6b-928a-c9d1389c6ef8">Testicular cancer, combination chemotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Testicular cancer, combination chemotherapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Testicular germ cell tumor, metastatic, good risk:</i></b>
<b>IV:</b> 100 mg/m<sup>2</sup> on days 1 to 5 every 3 weeks (in combination with cisplatin) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17351252','lexi-content-ref-16361627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17351252','lexi-content-ref-16361627'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Testicular germ cell tumor, metastatic, intermediate or poor risk:</i></b>
<b>IV:</b> 100 mg/m<sup>2</sup> on days 1 to 5 every 3 weeks (in combination with bleomycin and cisplatin) for 4 cycles <b>or</b> 75 mg/m<sup>2</sup> on days 1 to 5 every 3 weeks (in combination with cisplatin, ifosfamide, and mesna) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9552027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9552027'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Testicular germ cell tumor, metastatic, high-dose regimens:</i></b>
<b>IV:</b> 750 mg/m<sup>2</sup>/day administered 5, 4, and 3 days before peripheral blood stem cell infusion (in combination with carboplatin); repeat for a second cycle after recovery of granulocyte and platelet counts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17652649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17652649'])">Ref</a></span>) <b>or</b> 400 mg/m<sup>2</sup>/day (beginning on cycle 3) on days 1, 2, and 3, with peripheral blood stem cell support, administered at 14- to 21-day intervals (in combination with carboplatin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17194908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17194908'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7b01353-4939-489d-be3f-eee58c23f909">Thymic carcinoma, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thymic carcinoma, locally advanced or metastatic (off-label use; based on limited data):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CODE regimen:</i>
<b>IV: </b>80 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with vincristine, doxorubicin, and cisplatin) during weeks 1, 3, 5, 7, and 9 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12942558']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12942558'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VIP regimen:</i>
<b>IV: </b>75 mg/m<sup>2</sup> on days 1 to 4 (in combination with ifosfamide, mesna, cisplatin, and colony-stimulating growth factor support) every 3 weeks for up to 4 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11391579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11391579'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40e105fe-3a89-46d0-b103-ac2727176a26">Thymoma, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thymoma, locally advanced or metastatic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>PE regimen:</i>
<b>IV: </b>120 mg/m<sup>2</sup> on days 1, 2, and 3 every 3 weeks (in combination with cisplatin) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8622029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8622029'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VIP regimen:</i>
<b>IV: </b>75 mg/m<sup>2</sup> on days 1 to 4 (in combination with ifosfamide, mesna, cisplatin, and colony-stimulating growth factor support) every 3 weeks for up to 4 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11391579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11391579'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abf998a3-72fe-40c4-a3e9-57f7fa6c7507">Unknown primary adenocarcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Unknown primary adenocarcinoma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 50 mg once daily on days 1, 3, 5, 7, and 9 alternating with 100 mg once daily on days 2, 4, 6, 8, and 10 every 3 weeks (in combination with paclitaxel and carboplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11135228','lexi-content-ref-16877720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11135228','lexi-content-ref-16877720'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991451"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Empiric dose adjustments of etoposide are based on correlation between kidney function with AUC and risk of adverse hematologic events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8070031','lexi-content-ref-8431968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8070031','lexi-content-ref-8431968'])">Ref</a></span>). Physiologic elimination of etoposide is complex with extensive interpatient variability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3297462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3297462'])">Ref</a></span>); kidney function is one consideration for dosage in context of additional factors influencing drug disposition and toxicity (patient age, blood albumin, UDP-glucuronosyltransferase 1A1 activity, liver function, concurrent medications) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8070031','lexi-content-ref-17151191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8070031','lexi-content-ref-17151191'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV, oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 50 mL/minute: Administer 75% of the usual indication-specific dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3772420','lexi-content-ref-3697995','lexi-content-ref-8558207','lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3772420','lexi-content-ref-3697995','lexi-content-ref-8558207','lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: Administer 50% of the usual indication-specific dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3697995','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3697995','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b>
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, oral: </b>No dosage adjustment necessary. Clinical data is insufficient to support empiric etoposide dosage adjustment for ARC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3004725','lexi-content-ref-9027788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3004725','lexi-content-ref-9027788'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> Initial: Administer 50% of the usual indication-specific dose; can administer independently of hemodialysis schedule (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14679119','lexi-content-ref-20118214','lexi-content-ref-22868508','lexi-content-ref-9027788','lexi-content-ref-18758316','lexi-content-ref-34587368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14679119','lexi-content-ref-20118214','lexi-content-ref-22868508','lexi-content-ref-9027788','lexi-content-ref-18758316','lexi-content-ref-34587368'])">Ref</a></span>). <b>Note:</b> Two case series suggest that etoposide pharmacokinetics are relatively unaltered in hemodialysis patients. Given the extensive interpatient variability in etoposide pharmacokinetics, doses may be cautiously increased based on intent of therapy (curative versus noncurative), tolerability, and response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3004725','lexi-content-ref-12556954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3004725','lexi-content-ref-12556954'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8611379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8611379'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, oral:</b> Initial: Administer 50% of the usual indication-specific dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8611379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8611379'])">Ref</a></span>). <b>Note:</b> Given the extensive interpatient variability in etoposide pharmacokinetics, doses may be cautiously titrated based on intent of therapy (curative versus noncurative), tolerability, and response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b>
<b>Note:</b> Close monitoring of response and adverse reactions (eg, hematologic toxicity, mucositis) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, oral:</b> Dose as for CrCl &lt;15 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Note:</b> Close monitoring of response and adverse reactions (eg, hematologic toxicity, mucositis) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, oral:</b> Dose as for CrCl &lt;15 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988760"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have also been recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Donelli 1998: Liver dysfunction may reduce the metabolism and increase the toxicity of etoposide. Normal doses of IV etoposide should be given to patients with liver dysfunction (dose reductions may result in subtherapeutic concentrations); however, use caution with concomitant liver dysfunction (severe) and renal dysfunction as the decreased metabolic clearance cannot be compensated by increased renal clearance.</p>
<p style="text-indent:-2em;margin-left:4em;">Floyd 2006: Bilirubin 1.5 to 3 mg/dL or AST &gt;3 times ULN: Administer 50% of dose</p>
<p style="text-indent:-2em;margin-left:4em;">King 2001, Koren 1992: Bilirubin 1.5 to 3 mg/dL or AST &gt;180 units/L: Administer 50% of dose</p></div>
<div class="block doo drugH1Div" id="F20344389"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society of Clinical Oncology guidelines for appropriate chemotherapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup> (<b>Note:</b> Excludes hematopoietic stem cell transplantation dosing):</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society for Blood and Marrow Transplantation practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight for calculation of BSA for BSA-based dosing and utilize adjusted body weight 25% (ABW25) for mg/kg dosing for hematopoietic cell transplant conditioning regimens in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24462742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24462742'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">ABW25: Adjusted weight (kg) = Ideal body weight (kg) + 0.25 [actual weight (kg) − ideal body weight (kg)]</p></div>
<div class="block dot drugH1Div" id="F14934910"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">ANC &lt;500/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup>: Withhold treatment until recovery.</p>
<p style="text-indent:-2em;margin-left:4em;">Hypotension: Interrupt infusion and administer IV hydration and supportive care; decrease infusion rate upon reinitiation.</p>
<p style="text-indent:-2em;margin-left:4em;">Infusion (hypersensitivity) reactions: Interrupt infusion (medications for the treatment of anaphylaxis should be available for immediate use during etoposide IV administration).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe adverse reactions (nonhematologic): Reduce dose or discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrathecal/Intraventricular (off-label route): </b>Arachnoiditis: May be managed with corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16583432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16583432'])">Ref</a></span>). Corticosteroids were administered prophylactically in some reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26258900','lexi-content-ref-25879815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26258900','lexi-content-ref-25879815'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F169284"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F169311"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13292" href="/d/html/13292.html" rel="external">see "Etoposide: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose, frequency, number of doses, and start date may vary by protocol and treatment phase; refer to individual protocols. Pediatric dosing units (eg, mg/<b>kg</b>, mg/m<sup>2</sup>) and routes (eg, IV, continuous IV infusion, intraventricular) are variable depending upon protocol/regimen; use caution. Etoposide is associated with a low emetic risk (intravenous) and moderate emetic risk (oral); antiemetics may be recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637','lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637','lexi-content-ref-30729654'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="325fe1c9-065e-450c-9429-246476af14bd">Acute lymphoblastic leukemia, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia (ALL), relapsed/refractory:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Hijiya 2011: <i>Induction and Consolidation</i>: Children and Adolescents: IV: 100 mg/m<sup>2</sup> over 2 hours for 5 consecutive days in Induction (in combination with cyclophosphamide and clofarabine) and 4 consecutive days in Consolidation (in combination with cyclophosphamide and clofarabine).</p>
<p style="text-indent:-2em;margin-left:4em;">Parker 2010: ALL R3 Protocol:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Phase 2 Consolidation</i>: IV: 100 mg/m<sup>2</sup> once daily on days 15 to 19 (in combination with other chemotherapeutic agents).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Phase 5 before continuation</i>: IV: 150 mg/m<sup>2</sup> once daily on days 42, 49, 99, and 106 (in combination with other chemotherapeutic agents).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2647719a-6466-4817-b8e3-9f6b3c1e3136">Acute lymphoblastic leukemia of infancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia (ALL) of infancy:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Dreyer 2011; Dreyer 2015: Infants and Children &lt;1 year at diagnosis: IV: 100 mg/m<sup>2</sup> over 2 hours once daily for 5 consecutive days; specific regimen days and combination chemotherapeutic agents variable dependent on protocol phase; refer to specific protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">Tomizawa 2020: <b>Note</b>: Specific regimen days and combination chemotherapeutic agents variable dependent on protocol phase.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;1 year at diagnosis:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Low risk; Regimen A:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Early consolidation and re-induction: <b>Note:</b> Used in combination with other chemotherapy; varies with phase of the regimen (refer to specific protocols).</p>
<p style="text-indent:-2em;margin-left:12em;">Infants &lt;2 months: IV: 66.7 mg/m<sup>2</sup> over 2 hours once daily for 4 consecutive days.</p>
<p style="text-indent:-2em;margin-left:12em;">Infants ≥2 to 3 months: IV: 75 mg/m<sup>2</sup> over 2 hours once daily for 4 consecutive days.</p>
<p style="text-indent:-2em;margin-left:12em;">Infants &gt;3 months and Children: IV: 100 mg/m<sup>2</sup> over 2 hours once daily for 4 consecutive days.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance:</p>
<p style="text-indent:-2em;margin-left:12em;">Infants &lt;2 months: IV: 100 mg/m<sup>2</sup> over 2 hours once daily on days 14 and 42.</p>
<p style="text-indent:-2em;margin-left:12em;">Infants ≥2 to 3 months: IV: 112.5 mg/m<sup>2</sup> over 2 hours once daily on days 14 and 42.</p>
<p style="text-indent:-2em;margin-left:12em;">Infants &gt;3 months and Children: IV: 150 mg/m<sup>2</sup> over 2 hours once daily on days 14 and 42.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Intermediate and high risk; Regimen B:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Early and late consolidation and maintenance B-I (cycles 2 and 4):</p>
<p style="text-indent:-2em;margin-left:12em;">Infants &lt;2 months: IV: 66.7 mg/m<sup>2</sup> over 2 hours once daily for 5 consecutive days.</p>
<p style="text-indent:-2em;margin-left:12em;">Infants ≥2 to 3 months: IV: 75 mg/m<sup>2</sup> over 2 hours once daily for 5 consecutive days.</p>
<p style="text-indent:-2em;margin-left:12em;">Infants &gt;3 months and Children: IV: 100 mg/m<sup>2</sup> over 2 hours once daily for 5 consecutive days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0616790-4d1f-431a-acc0-3bce79aef7bb">Acute myeloid leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia (AML):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Gamis 2014: <b>Note: </b>Some aspects of protocol dosing presented in previous reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21766293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21766293'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Remission Induction: ADE (10 + 3 + 5) and ADE (8 + 3 + 5) regimens:</i></p>
<p style="text-indent:-2em;margin-left:10em;">BSA &lt;0.6 m<sup>2</sup>: IV: 3.3 mg/<b>kg</b> once daily for 5 days (in combination with cytarabine and daunorubicin).</p>
<p style="text-indent:-2em;margin-left:10em;">BSA ≥0.6 m<sup>2</sup>: IV: 100 mg/m<sup>2 </sup>once daily for 5 days (in combination with cytarabine and daunorubicin).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Intensification I: AE regimen:</i></p>
<p style="text-indent:-2em;margin-left:10em;">BSA &lt;0.6 m<sup>2</sup>: IV: 5 mg/<b>kg</b> once daily for 5 days (in combination with cytarabine).</p>
<p style="text-indent:-2em;margin-left:10em;">BSA ≥0.6 m<sup>2</sup>: IV: 150 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine).</p>
<p style="text-indent:-2em;margin-left:4em;">Gibson 2011:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;17 years: <b>Note:</b> For infants, the full dose was reduced by 25%:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Induction Course 1 (ADE 10 + 3 + 5, MAE 3 + 10 + 5 regimens):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Infants: IV: 75 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine and daunorubicin or mitoxantrone).</p>
<p style="text-indent:-2em;margin-left:10em;">Children and Adolescents &lt;17 years: IV: 100 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine and daunorubicin or mitoxantrone).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Induction Course 2 (ADE 8 + 3 + 5, MAE 3 + 8 + 5 regimens):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Infants: IV: 75 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine and daunorubicin or mitoxantrone).</p>
<p style="text-indent:-2em;margin-left:10em;">Children and Adolescents &lt;17 years: IV: 100 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine and daunorubicin or mitoxantrone).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3af7be48-9503-48e3-b4fb-fbcfba6a47a9">CNS tumors, malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS tumors, malignant (medulloblastoma, primitive neuroectodermal tumors [PNET], ependymoma, and brainstem glioma):</b> Limited data available; multiple regimens reported:</p>
<p style="text-indent:-2em;margin-left:4em;">Chi 2004; Fangusaro 2008: Head Start II regimen:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;10 years:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Induction</i>: IV: 4 mg/<b>kg</b> once daily for 2 days on day 2 and 3 of a 21-day cycle (cycle starts on day 0) for 4 to 5 cycles (in combination with cisplatin, vincristine, cyclophosphamide/mesna and high-dose methotrexate/leucovorin).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Consolidation with autologous peripheral blood stem cell rescue</i>: IV: 250 mg/m<sup>2</sup> for 3 doses on day −5 to −3 (in combination with carboplatin and thiotepa).</p>
<p style="text-indent:-2em;margin-left:4em;">Taylor 2003: Children ≥3 years and Adolescents: IV: 100 mg/m<sup>2</sup>/dose once daily on days 1, 2, and 3 (in combination with vincristine and carboplatin or cyclophosphamide) every 3 weeks for 4 cycles prior to radiation.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9bd4b7ac-beb3-4ad5-bee1-b763a2365264">CNS nongerminomatous germ cell tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS nongerminomatous germ cell tumor (NGGCT):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction Cycles 1, 3, and 5</i>: IV: 90 mg/m<sup>2</sup> once daily for 3 days on days 1 to 3 in combination with carboplatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26101244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26101244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction Cycles 2, 4, and 6</i>: IV: 90 mg/m<sup>2</sup> once daily for 5 days on days 1 to 5 in combination with ifosfamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26101244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26101244'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="78afbc64-414a-438a-9034-0db780da7500">CNS tumors; relapsed, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS tumors; relapsed, metastatic: </b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11384092','lexi-content-ref-27147083','lexi-content-ref-25017328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11384092','lexi-content-ref-27147083','lexi-content-ref-25017328'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Intraventricular (using preservative-free formulation): 0.25 mg. Administer via an Ommaya or Rickham reservoir once daily for 5 consecutive days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Intraventricular (using preservative-free formulation): 0.5 mg Administer via an Ommaya or Rickham reservoir once daily for 5 consecutive days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aee220af-0844-4780-b143-cde0d52e0c13">Ewing sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma: </b>Limited data available; multiple regimens reported:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IE regimen</i>: Children and Adolescents: IV: 100 mg/m<sup>2</sup> over 1 hour once daily for 5 days on days 1 to 5 of a 21-day cycle in combination with ifosfamide; frequency of cycles, and alternating chemotherapy combinations vary based on protocol (eg, cyclophosphamide, vincristine, doxorubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12594313','lexi-content-ref-7595741','lexi-content-ref-26508901','lexi-content-ref-17584910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12594313','lexi-content-ref-7595741','lexi-content-ref-26508901','lexi-content-ref-17584910'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VAC/IE regimen</i>: Children and Adolescents: IV: 150 mg/m<sup>2</sup> once daily for 3 doses on days 1 to 3 in combination with ifosfamide every 3 weeks alternating with VAC (vincristine, doxorubicin, and cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16541446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16541446'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relapsed, refractory: ICE regimen</i>: Children and Adolescents: IV: 100 mg/m<sup>2</sup> for 5 days every 3 to 4 weeks for up to 12 cycles in combination with carboplatin, ifosfamide, and mesna; or may follow with 2 courses of CAV (cyclophosphamide, doxorubicin, and vincristine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16532434','lexi-content-ref-15503297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16532434','lexi-content-ref-15503297'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41fcb3a2-3718-46cb-a41a-e5838d6fd66e">Hematopoietic stem cell transplant conditioning regimen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplant (HSCT) conditioning regimen:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Infant</i>
<i> ALL conditioning regimen:</i> Infants and Children diagnosed at &lt;1 year: IV: 60 mg/<b>kg</b>/dose over 12 hours on day −4 (in combination with busulfan and cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32845001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32845001'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ALL conditioning regimen</i>: Infants ≥6 months, Children, and Adolescents: IV: 20 mg/<b>kg</b> once daily on days −4 to −2 (in combination with busulfan and fludarabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25255163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25255163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Medulloblastoma conditioning regimen</i>: Children ≥7 years and Adolescents: IV: 250 mg/m<sup>2</sup> on days −5, −4, and −3 (in combination with thiotepa and high-dose carboplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20167818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20167818'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f86a6d7e-6c6e-408e-a183-ae5d2b796973">Hemophagocytic lymphohistiocytosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophagocytic lymphohistiocytosis (HLH): </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial therapy</i>: IV: 150 mg/m<sup>2</sup> twice weekly for weeks 1 and 2 then once weekly for 8 weeks, in combination with cyclosporine and dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28935695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28935695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuation therapy:</i> IV: 150 mg/m<sup>2</sup> every 2 weeks until HSCT or for 40 weeks, in combination with cyclosporine and dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28935695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28935695'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>High risk: BEACOPP regimen</i>: Children and Adolescents: IV: 200 mg/m<sup>2</sup> on days 0, 1, and 2 of a 21-day treatment cycle for 4 cycles (in combination with bleomycin, cyclophosphamide, doxorubicin, vincristine, prednisone, and procarbazine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21079154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21079154'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermediate or high risk: ABVE-PC regimen</i>: Children and Adolescents: IV: 125 mg/m<sup>2</sup> over 1 hour once daily for 3 days of a 21-day cycle for 2 to 4 cycles (in combination with doxorubicin, vincristine, cyclophosphamide, prednisone, and bleomycin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25542311','lexi-content-ref-25311218','lexi-content-ref-19584400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25542311','lexi-content-ref-25311218','lexi-content-ref-19584400'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2505cf47-016f-4504-bb13-dd5aa2b13a0d">Lymphoma, primary mediastinal B-cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphoma, primary mediastinal B-cell (PMLBL):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose adjusted (DA)-EPOCH regimen </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34570655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34570655'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: Dose level 1: IV: 50 mg/m<sup>2</sup>/day on days 1 to 4 as a continuous infusion in combination with doxorubicin, vincristine, cyclophosphamide, and prednisone.</p>
<p style="text-indent:-2em;margin-left:8em;">Dosage adjustment: Dose-adjusted for subsequent course every 3 weeks based on neutrophil and platelet counts during nadir to ensure highest tolerated doses are given while minimizing toxicity; within the protocol the dose ranges from 50 mg/m<sup>2</sup>/day (Level 1) to 124.4 mg/m<sup>2</sup>/day (Level 6). Measure blood counts twice weekly (3 days apart) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34570655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34570655'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="711bf705-f632-42d0-8dd1-89a216b52c12">Malignant solid tumors, relapsed or metastatic disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant solid tumors, relapsed or metastatic disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IE regimen</i>: Children and Adolescents: IV: 100 mg/m<sup>2</sup> over 1 hour once daily for 3 to 5 days every 3 weeks in combination with ifosfamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8448755','lexi-content-ref-27569442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8448755','lexi-content-ref-27569442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ICE regimen</i>: Children and Adolescents: IV: 100 mg/m<sup>2</sup>/day for 5 days on days 0 to 4 every 3 weeks for up to 12 cycles in combination with carboplatin, ifosfamide, and mesna (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15503297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15503297'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9620891e-d91b-4073-80a0-b2f9c15bd320">Neuroblastoma, high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, high-risk:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥1 year and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction</i>: IV: 100 to 200 mg/m<sup>2</sup>/dose infused over 1 to 2 hours once daily for 3 to 5 consecutive days (in combination with other chemotherapy agents) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12439032','lexi-content-ref-15611504','lexi-content-ref-17479288','lexi-content-ref-17279006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12439032','lexi-content-ref-15611504','lexi-content-ref-17479288','lexi-content-ref-17279006'])">Ref</a></span>); other reported regimens include 100 mg/m<sup>2</sup>/dose on day 2 and 5 (in combination with cisplatin, doxorubicin, and cyclophosphamide) every 28 days for 5 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10519894']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10519894'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Myeloablative therapy with stem cell rescue (tandem transplant):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;12 kg:</p>
<p style="text-indent:-2em;margin-left:10em;">GFR ≥100 mL/minute/1.73 m<sup>2</sup>: IV: 10 mg/<b>kg </b>over 24 hours × 4 doses in combination with carboplatin and melphalan beginning 7 days prior to stem cell infusion, administered in tandem with thiotepa and cyclophosphamide regimen followed by stem cell rescue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31454045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31454045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">GFR ≥60 and &lt;100 mL/minute/1.73 m<sup>2</sup>: IV: 6.7 mg/<b>kg</b> over 24 hours × 4 doses in combination with carboplatin and melphalan beginning 7 days prior to stem cell infusion, administered in tandem with thiotepa and cyclophosphamide regimen followed by stem cell rescue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31454045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31454045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 kg and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">GFR ≥100 mL/minute/1.73 m<sup>2</sup>: IV: 300 mg/m<sup>2</sup> over 24 hours × 4 doses in combination with carboplatin and melphalan beginning 7 days prior to stem cell infusion, administered in tandem with thiotepa and cyclophosphamide regimen followed by stem cell rescue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31454045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31454045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">GFR ≥60 and &lt;100 mL/minute/1.73 m<sup>2</sup>: IV: 200 mg/m<sup>2</sup> over 24 hours × 4 doses in combination with carboplatin and melphalan beginning 7 days prior to stem cell infusion, administered in tandem with thiotepa and cyclophosphamide regimen followed by stem cell rescue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31454045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31454045'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="99f6fc92-5e20-46c5-a7d9-0504aaf1e363">Retinoblastoma, extraocular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Retinoblastoma, extraocular: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &lt;10 kg: IV: 3.3 mg/<b>kg</b> once daily on days 1, 2, and 3 of a 21-day treatment cycle (in combination with carboplatin) alternating cycles with idarubicin and vincristine for a total of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12518344']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12518344'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≥10 kg: IV: 100 mg/m<sup>2</sup> once daily on days 1, 2, and 3 of a 21-day treatment cycle (in combination with carboplatin) alternating cycles with idarubicin and vincristine for a total of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12518344']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12518344'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e8cead17-5b33-4326-9157-7fee0fdfa8f5">Wilms tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilms tumor:</b> Limited data available: <i>ICE regimen</i>: Children and Adolescents: IV: 100 mg/m<sup>2</sup> once daily for 3 to 5 doses (in combination with ifosfamide and carboplatin); repeat cycle every 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11996479','lexi-content-ref-18996004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11996479','lexi-content-ref-18996004'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity: </b>The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">ANC &lt;500/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup>: Withhold treatment until recovery.</p>
<p style="text-indent:-2em;margin-left:6em;">Hypotension: Interrupt infusion and administer IV hydration and supportive care; decrease infusion rate upon reinitiation.</p>
<p style="text-indent:-2em;margin-left:6em;">Infusion (hypersensitivity) reactions: Interrupt infusion (medications for the treatment of anaphylaxis should be available for immediate use during etoposide IV administration).</p>
<p style="text-indent:-2em;margin-left:6em;">Severe adverse reactions (nonhematologic): Reduce dose or discontinue treatment.</p></div>
<div class="block dorp drugH1Div" id="F51109941"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosage adjustment may be indication specific; consult institutional protocols.</p>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: Dosage adjustments are not provided in the manufacturer's labeling for pediatric patients; however, the manufacturer recommends the following for adult patients.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 50 mL/minute: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL minute: Data not available; consider further dose reductions.</p>
<p style="text-indent:-2em;margin-left:4em;">Alternate adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis/peritoneal dialysis (PD) (after dialysis on dialysis days): Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): Administer 75% of dose and reduce for hyperbilirubinemia.</p></div>
<div class="block dohp drugH1Div" id="F51109942"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: The following adjustment has been recommended based primarily on experience in adult patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473644'])">Ref</a></span>):</p>
<p style="text-indent:0em;margin-left:2em;">Bilirubin 1.5 to 3 mg/dL or AST &gt;3 times ULN: Administer 50% of dose.</p></div>
<div class="block adr drugH1Div" id="F169248"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">The following may occur with higher doses used in stem cell transplantation: Alopecia, ethanol intoxication, hepatitis, hypotension (infusion-related), metabolic acidosis, mucositis, nausea and vomiting (severe), secondary malignancy, skin lesions (resembling Stevens-Johnson syndrome).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (8% to 66%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (31% to 43%), anorexia (10% to 13%), diarrhea (1% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (60% to 91%; grade 4: 3% to 17%; nadir: 7 to 14 days; recovery: by day 20), thrombocytopenia (22% to 41%; grades 3/4: 1% to 20%; nadir: 9 to 16 days; recovery: by day 20), anemia (≤33%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (1% to 2%; due to rapid infusion)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Peripheral neuropathy (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Stomatitis (1% to 6%), abdominal pain (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactoid reaction (intravenous: 1% to 2%; oral capsules: &lt;1%; including bronchospasm, chills, dyspnea, fever, tachycardia)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Amenorrhea, apnea (hypersensitivity-associated), back pain, constipation, cortical blindness (transient), cough, cyanosis, diaphoresis, drowsiness, dysphagia, erythema, esophagitis, extravasation (induration/necrosis), facial swelling, fatigue, fever, hyperpigmentation, hypersensitivity reaction, interstitial pneumonitis, ischemic heart disease, laryngospasm, maculopapular rash, malaise, metabolic acidosis, mucositis, myocardial infarction, optic neuritis, ovarian failure, pruritic erythematous rash, pruritus, pulmonary fibrosis, radiation-recall phenomenon (dermatitis), reversible posterior leukoencephalopathy syndrome (RPLS), seizure, skin rash, Stevens-Johnson syndrome, tongue edema, toxic epidermal necrolysis, toxic megacolon, urticaria, vasospasm, weakness</p></div>
<div class="block coi drugH1Div" id="F169262"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to etoposide or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment</p></div>
<div class="block war drugH1Div" id="F169245"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Severe myelosuppression with resulting infection or bleeding may occur. Myelosuppression is dose related and dose limiting. Granulocyte and platelet nadirs typically occur 7 to 14 days or 9 to 16 days, respectively, after administration; hematologic recovery usually occurs by day 20.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Etoposide IV is an irritant (Pérez Fidalgo 2012); tissue irritation and inflammation have occurred following extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: May cause anaphylactic-like reactions manifested by chills, fever, tachycardia, bronchospasm, dyspnea, and hypotension. In addition, facial/tongue swelling, coughing, chest tightness, cyanosis, laryngospasm, diaphoresis, hypertension, back pain, loss of consciousness, and flushing have also been reported less commonly. Incidence is primarily associated with IV administration (up to 2%) compared to oral administration (&lt;1%). High drug concentration and rate of infusion, as well as presence of polysorbate 80 and benzyl alcohol in the etoposide IV formulation, have been suggested as contributing factors to the development of hypersensitivity reactions. Etoposide IV formulations may contain polysorbate 80 and/or benzyl alcohol, while etoposide phosphate (the water-soluble prodrug of etoposide) IV formulation does not contain either vehicle. Case reports have suggested that etoposide phosphate has been used successfully in patients with previous hypersensitivity reactions to etoposide (Collier 2008; Siderov 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Hypotension may occur due to rapid administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancies: Secondary acute leukemias have been reported with etoposide, either as monotherapy or in combination with other chemotherapy agents.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoalbuminemia: Use with caution in patients with low serum albumin; may increase risk for toxicities.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥65 years of age may be more likely to develop severe myelosuppression and/or GI effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatrics: The use of concentrations higher than recommended were associated with higher rates of anaphylactic-like reactions in children.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alcohol: Injectable formulation contains alcohol (~30% to 33% v/v); may contribute to adverse reactions, especially with higher etoposide doses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F169256"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toposar: 100 mg/5 mL (5 mL [DSC]); 500 mg/25 mL (25 mL [DSC]); 1 g/50 mL (50 mL [DSC]) [contains alcohol, usp, polyethylene glycol 300 (peg-6), polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL); 500 mg/25 mL (25 mL); 1 g/50 mL (50 mL)</p></div>
<div class="block geq drugH1Div" id="F169241"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323139"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Etoposide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $100.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Etoposide Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 gm/50 mL (per mL): $1.82 - $2.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $1.20 - $2.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/25 mL (per mL): $1.82 - $2.99</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866854"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">VePesid: 50 mg [contains ethylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (5 mL, 10 mL, 20 mL, 25 mL, 50 mL)</p></div>
<div class="block adm drugH1Div" id="F169259"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Doses ≤200 mg/day may be administered as a single once daily dose; doses &gt;200 mg should be given in 2 divided doses. Based on a small pharmacokinetic study, food does not appear to significantly interfere with the bioavailability of a 100 mg etoposide dose (oral capsules); therefore, etoposide capsules may be administered in a fed or fasted state (with or without food) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2994705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2994705'])">Ref</a></span>). If necessary, the injection may be used to prepare an oral solution for oral administration (see Extemporaneously Prepared).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer standard doses over at least 30 to 60 minutes to minimize the risk of hypotension. Higher (off-label) doses used in transplantation may be infused over longer time periods depending on the protocol (refer to protocol for infusion duration). Etoposide injection contains polysorbate 80 which may cause leaching of DEHP, a plasticizer contained in PVC tubing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16595068','lexi-content-ref-11975699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16595068','lexi-content-ref-11975699'])">Ref</a></span>). Administration through non-PVC (low sorbing) tubing will minimize patient exposure to DEHP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16595068','lexi-content-ref-11975699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16595068','lexi-content-ref-11975699'])">Ref</a></span>). Etoposide is an irritant; tissue irritation and inflammation have occurred following extravasation; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">IV concentrations &gt;0.4 mg/mL are very unstable and may precipitate within a few minutes. For large doses, where dilution to ≤0.4 mg/mL is not feasible, consideration should be given to slow infusion of the undiluted drug through a running normal saline, dextrose or saline/dextrose infusion; or use of etoposide phosphate. Due to the risk for precipitation, an inline filter may be used; etoposide solutions of 0.1 to 0.4 mg/mL may be filtered through a 0.22-micron filter without damage to the filter; etoposide solutions of 0.2 mg/mL may be filtered through a 0.22-micron filter without significant loss of drug.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrathecal/Intraventricular (off-label route): </b>In clinical reports, etoposide was administered over 2 minutes via an Ommaya or Rickham reservoir. Prior to administration, 5 to 6 mL of CSF fluid was drained for discarding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11384092','lexi-content-ref-26258900','lexi-content-ref-25879815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11384092','lexi-content-ref-26258900','lexi-content-ref-25879815'])">Ref</a></span>). Corticosteroids were administered as prophylaxis for chemical arachnoiditis in some reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26258900','lexi-content-ref-25879815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26258900','lexi-content-ref-25879815'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612790"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Etoposide is associated with a low emetic risk (intravenous) and moderate emetic risk (oral); antiemetics may be recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: In adults, doses ≤200 mg/day should be given as a single daily dose; doses &gt;200 mg should be given in 2 divided doses. If necessary, the injection may be used for oral administration either as an extemporaneous preparation or by mixing dose with orange juice, apple juice, or lemonade at a final concentration not to exceed 0.4 mg/mL (to improve palatability) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21275495','lexi-content-ref-1471649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21275495','lexi-content-ref-1471649'])">Ref</a></span>). Based on a small pharmacokinetic study, food does not appear to significantly interfere with the bioavailability of a 100 mg etoposide dose (oral capsules); therefore, etoposide capsules may be administered in a fed or fasted state (with or without food) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2994705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2994705'])">Ref</a></span>).​</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: For IV infusion only; do not administer by rapid IV injection or by intrathecal, intraperitoneal, or intrapleural routes due to possible severe toxicity. Etoposide injection contains polysorbate 80 which may cause leaching of diethylhexyl phthalate (DEHP), a plasticizer contained in polyvinyl chloride (PVC) tubing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16595068','lexi-content-ref-11975699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16595068','lexi-content-ref-11975699'])">Ref</a></span>). Administration through non-PVC (low sorbing) tubing will minimize patient exposure to DEHP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16595068','lexi-content-ref-11975699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16595068','lexi-content-ref-11975699'])">Ref</a></span>). Etoposide is an irritant; tissue irritation and inflammation have occurred following extravasation; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:6em;">Administer by continuous IV infusion or IV intermittent infusion over at least 60 minutes at a rate not to exceed 100 mg/m<sup>2</sup>/hour (or 3.3 mg/<b>kg</b>/hour) to minimize the risk of hypotension. Due to risk for precipitation, a 0.22-micron inline filter may be used. Hematopoietic stem cell transplantation conditioning regimens have infused etoposide through a central venous catheter over 4 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11149746','lexi-content-ref-10713624','lexi-content-ref-7989928','lexi-content-ref-8219241','lexi-content-ref-10068272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11149746','lexi-content-ref-10713624','lexi-content-ref-7989928','lexi-content-ref-8219241','lexi-content-ref-10068272'])">Ref</a></span>). Higher than recommended concentrations of etoposide infusions may crack hard plastic in chemo venting pins and infusion lines; inspect infusion solution for particulate matter and plastic devices for cracks and leaks.</p>
<p style="text-indent:-2em;margin-left:4em;">Intraventricular: In pediatric patients, doses were injected over 2 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11384092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11384092'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132492"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F169257"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer (oral and IV):</b> Treatment (first-line) of small cell lung cancer (in combination with other chemotherapeutic agents).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Testicular cancer (IV):</b> Treatment of refractory testicular tumors (injectable formulation) (in combination with other chemotherapeutic agents).</p></div>
<div class="block off-label drugH1Div" id="F25733575"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute lymphoblastic leukemia, relapsed/refractory; Acute myeloid leukemia, refractory; Adrenocortical carcinoma (advanced); AIDS-related Kaposi sarcoma; Brain metastases (due to breast or non-small cell lung cancers); Breast cancer, metastatic; Gestational trophoblastic neoplasia (high risk); Hemophagocytic lymphohistiocytosis; Hematopoietic stem cell transplant conditioning regimen; Hodgkin lymphoma; Merkel cell carcinoma (high risk); Multiple myeloma; Neuroendocrine tumors (metastatic carcinoma); Non-Hodgkin lymphoma; Non-small cell lung cancer; Ovarian cancer, epithelial, refractory; Ovarian germ cell tumors; Prostate cancer, castration resistant, metastatic; Sarcomas (rhabdomyosarcoma, Ewing sarcoma, osteosarcoma), refractory; Soft tissue sarcoma; Thymic carcinoma, locally advanced or metastatic; Thymoma, locally advanced or metastatic; Unknown primary adenocarcinoma</p></div>
<div class="block mst drugH1Div" id="F169342"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Etoposide may be confused with teniposide</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Etoposide may be confused with etoposide phosphate (a prodrug of etoposide which is rapidly converted in the plasma to etoposide)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">VePesid may be confused with Versed</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F169328"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F169250"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atovaquone: May increase the serum concentration of Etoposide. Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May decrease the metabolism of Etoposide. Management: Consider reducing the dose of etoposide by 50% if the patient is receiving, or has recently received, cyclosporine. Monitor for increased toxic effects of etoposide if cyclosporine is initiated, the dose is increased, or it has been recently discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Etoposide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Etoposide. Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide. If combined, monitor patients closely for diminished etoposide response and need for etoposide dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May decrease the serum concentration of Etoposide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Etoposide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Etoposide may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49305367"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">In females of reproductive potential, product labeling for etoposide phosphate notes that it may cause amenorrhea, infertility, or premature menopause; effective contraception should be used during therapy and for at least 6 months after the last dose. In males, azoospermia, oligospermia, or permanent loss of fertility may occur. In addition, spermatozoa and testicular tissue may be damaged. Males with female partners of reproductive potential should use condoms during therapy and for at least 4 months after the last dose.</p></div>
<div class="block pri drugH1Div" id="F2565787"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in animal reproduction studies. Fetal growth restriction and newborn myelosuppression have been observed following maternal use of regimens containing etoposide during pregnancy (NTP 2013; ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided during in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p></div>
<div class="block brc drugH1Div" id="F14934871"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Etoposide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Based on data from one case report, concentrations are below the limit of detection 24 hours after the last dose (Azuno 1995). Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F169254"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential at baseline, prior to each cycle, and as clinically necessary; liver function (bilirubin, ALT, AST), albumin, renal function tests; monitor vital signs (BP); monitor for signs of an infusion reaction. Monitor for secondary malignancies. Intrathecal/intraventricular etoposide (off-label route): Monitor for signs/symptoms of arachnoiditis. Oral etoposide: Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F169244"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Etoposide has been shown to delay transit of cells through the S phase and arrest cells in late S or early G<sub>2</sub> phase. The drug may inhibit mitochondrial transport at the NADH dehydrogenase level or inhibit uptake of nucleosides into HeLa cells. It is a topoisomerase II inhibitor and appears to cause DNA strand breaks. Etoposide does not inhibit microtubular assembly.</p></div>
<div class="block phk drugH1Div" id="F169261"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Significant inter- and intrapatient variation</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Average V<sub>d</sub>: Children: 10 L/m<sup>2</sup>; Adults: 7 to 17 L/m<sup>2</sup>; poor penetration across the blood-brain barrier; CSF concentrations &lt;5% of plasma concentrations</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 94% to 98%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, via CYP3A4 and 3A5, to various metabolites; in addition, conversion of etoposide to the O-demethylated metabolites (catechol and quinine) via prostaglandin synthases or myeloperoxidase occurs, as well as glutathione and glucuronide conjugation via GSTT1/GSTP1 and UGT1A1 (Yang 2009)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~50% (range: 25% to 75%)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: IV: Normal renal/hepatic function: Children: 6 to 8 hours: Adults: 4 to 11 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: IV: Urine (~55% as unchanged drug) in 24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: IV: Urine (56%; 45% as unchanged drug) within 120 hours; feces (44%) within 120 hours</p></div>
<div class="block phksp drugH1Div" id="F51154116"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Total body clearance is reduced, AUC is increased, and V<sub>d</sub> is lower.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F169265"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Etoposid | Vepesid</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Citodox | Etocris | Etoposido | Etoposido delta farma | Etoposido glenmark | Etoposido rontag | Etoposido servycal | Etoposido varifarm | Euvaxon | Labimion | Neoplaxol | Optasid | Percas | Vepesid | Vepesid vp-16</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Abiposid | Etoposid | Etoposid accord | Etoposid ebewe | Vepesid</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Vepesid</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Celltop | Eposin | Etoposide accord | Vepesid</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Etoposide accord | Etoposide actavis | Etosid | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Eposido | Etomerase | Etopos | Etoposideo | Etoposido | Etosin | Eunades cs | Evoposdo | Posidon | Tevaetopo | Vepesid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Etoposid ebewe | Etoposid fresenius | Etoposid Proreo | Etoposid Sandoz | Etoposid teva | Etoposide Bigmar | Etoposide bvi | Etoposide Pfizer | Etoposide teva | Vepesid</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Etopul | Oncosid</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bristol Vp-16 | Epsidox | Etoposido | Vepesid | Vp-16</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bo rui | Hai wei lin | Lastet | Vepesid | Wei ke</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Etoposido | Etosid | Oncoposido | Vepesid</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Etoposid | Etoposid ebewe | Etoposide accord | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Eto | Etomedac | Etoposid accord | Etoposid Oncotrade | Etoposid Sandoz | Exitop | Lastet | Neoposid | Onkoposid | Riboposid | Vepesid | Vepesid j | Vepesid k</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Fytosid</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Etoposido | Etoposido kemex | Vp gen</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Etoposid | Etoposide accord | Etoposide kabi | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Etoposid ebewe | Etoposide merck | Etopul | Etosid | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Etoposido accord | Etoposido Ferrer | Etoposido sandoz | Etoposido Tevagen | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Actitop | Lastet</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Etoposid fresenius | Etoposid mayne | Etoposide accord | Exitop | Vepesid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Celltop | Etoposide accord | Etoposide dakota | Etoposide merck | Etoposide Sandoz | Etoposide teva | Etoposide Winthrop | Vepeside</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Etoposide dup | Vepesid</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Etobion | Etoposide pharmachemie | Etoposide teva | Etoposide/Ebewe | Etoposide/pharmachemie | Vepesid</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Etoposid ebewe | Sintopozid | Vepesid</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Etoposide ebewe | Etoposide Pfizer | Etoposide Sandoz | Vepesid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Etoposid ebewe | Etoposide accord | Etoposide teva | Lastet | Sintopozid | Vepesid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Etoposide Pfizer | Etopul | Lastet | Posyd | Vepesid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vepesid</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Vepesid</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Actitop | Adside | Beposid | Bioposide | Ethopul | Etolon | Etopide | Etoplast | Etosid | Fytop | Fytosid | Lastet | Oncosid | Placid | Posid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Etoposide accord | Etoposide crinos | Etoposide fidia | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Etoposid</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bioposide | Distipe | Etoglen | Etoglob | Fytosid | Sedol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acid V | Alvogen etoposide | Aside | Aside v | Epocin | Eposin | Eps | Epside | Esten | Etopul | Lastet | Lastet S | Reyon etoposide | Vepesid</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Etoposid</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Etoposide mylan | Vepesid | Vepside</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Celltop | Eto gry | Etopos | Etoposid | Etoposide accord | Etoposide kabi | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Vepesid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Etoposide accord | Etoposide ebewe | Etoposide kabi | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Etoposide mylan | Vepeside</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cavep | Cryosid | Entaplen | Etopos | Etoposido | Etoposido gi kendr | Tosuben | Vepesid | Vp tec</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Etoplast | Etosid | Fytosid | Lastet | Posid | Vepesid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Etoposide accord | Etoposide ebewe | Etoposide Eurocept | Etoposide fresenius kabi | Etoposide hikma | Toposin | Vepesid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Eto gry | Etoposid accord | Etoposid ebewe | Etoposid fresenius kabi | Etoposid mayne | Etoposide accord | Etoposide fresenius kabi | Etoposide Sandoz | Vepesid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Vepesid</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Etocris | Etoposido | Lastet</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ebeposid | Etopa | Etopoxan | Etopul | Fytosid | Lastet | Mpl Toposid | Posid | Topresid | Vepesid</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Etopul | Etosid | Vepesid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Celltop | E.p.s. | Etomedac | Etoposid | Etoposid ebewe | Etoposid hexal | Etoposide Sandoz | Etoposide teva | Etopozyd accord | Etopul | Lastet | Sintopozid | Vepesid | Vepeside</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vepesid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Celltop | Etoposido | Etoposido accord | Etoposido APS | Etoposido teva | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Citodox | Etocris | Neoplaxol | Posidon | Vp gen</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Etoposid accord | Etoposid ebewe | Etoposide teva | Etopozida Kabi | Sintopozid | Vepesid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cytoposid | Cytoposide | Etoposid | Etoposid ebewe | Etoposide lans | Etoposide teva | Etosid | Fylotid | Fytosid | Lastet | Vepesid | Vero etoposide</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Etoposid | Sedol | Vepesid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Etoposid ebewe | Etoposid fresenius | Etoposid mayne | Etoposide accord | Exitop | Vepesid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ebeposide | Eposin | Etoposide teva | Fytosid | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ebeposid | Etopozid accord | Etopozid kabi | Vepesid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Etoposid | Etopozid accord | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Etopos | Etoposide abic | Etoposide dbl | Etoposide ebewe | Fytosid | Lastet | Sedol | Topo | Vepesid</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Etoposid ebewe | Etoposide mylan | Sintopozid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Etopex | Etoposid ebewe | Etosid | Lastet | Sintopozid | Vepesid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Eposide | Eposin | Fytosid | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Etoposid | Etoposid Lance | Etosid | Fytosid | Lastet | Vepesid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Actitop | Nzytop</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Etoposido | Etoposido FU | Neoplaxol | Vepesid</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Etonolver | Fytosid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Abic etoposide | Aspen etoposide | Eposin | Etoposide 100 mg/5 ml fresenius | Etoposide 1000 mg/50 ml fresenius | Etoposide 200 mg/10 ml fresenius | Etoposide 500 mg/25 ml fresenius | Etoposide Hexal | Lastet | P&amp;u etoposide | Vepesid</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Oncosid</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Eposin | Fytosid | Sedol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11996479">
<a name="11996479"></a>Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed wilms' tumor: A Children's Cancer Group report. <i>Ann Oncol</i>. 2002;13(3):460-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11996479/pubmed" id="11996479" target="_blank">11996479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19632716">
<a name="19632716"></a>Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379-386. doi: 10.1016/S0140-6736(09)60737-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/19632716/pubmed" id="19632716" target="_blank">19632716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23233709">
<a name="23233709"></a>Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. <i>J Clin Oncol</i>. 2013;31(2):280-286. doi:10.1200/JCO.2012.43.1817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/23233709/pubmed" id="23233709" target="_blank">23233709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2045861">
<a name="2045861"></a>Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. <i>J Clin Oncol</i>. 1991;9(7):1210-1214. doi: 10.1200/JCO.1991.9.7.1210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/2045861/pubmed" id="2045861" target="_blank">2045861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23649003">
<a name="23649003"></a>Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. <i>Clin Cancer Res</i>. 2013;19(13):3621-3630. doi: 10.1158/1078-0432.CCR-12-3791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/23649003/pubmed" id="23649003" target="_blank">23649003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3772420">
<a name="3772420"></a>Arbuck SG, Douglass HO, Crom WR, et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. <i>J Clin Oncol.</i> 1986;4(11):1690-1695. doi:10.1200/JCO.1986.4.11.1690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/3772420/pubmed" id="3772420" target="_blank">3772420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99, 171.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14736927">
<a name="14736927"></a>Arriagada R, Bergman B, Dunant A, et al; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. <i>N Engl J Med</i>. 2004;350(4):351-360. doi: 10.1056/NEJMoa031644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/14736927/pubmed" id="14736927" target="_blank">14736927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7847330">
<a name="7847330"></a>Azuno Y, Kaku K, Fujita N, Okubo M, Kaneko T, Matsumoto N. Mitoxantrone and etoposide in breast milk. <i>Am J Hematol</i>. 1995;48(2):131-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/7847330/pubmed" id="7847330" target="_blank">7847330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19452540">
<a name="19452540"></a>Berger M, Grignani G, Ferrari S, et al, “Phase 2 Trial of Two Courses of Cyclophosphamide and Etoposide for Relapsed High-Risk Osteosarcoma Patients,” <i>Cancer</i>, 2009, 115(13):2980-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/19452540/pubmed" id="19452540" target="_blank">19452540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28935695">
<a name="28935695"></a>Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. <i>Blood.</i> 2017;130(25):2728-2738. doi: 10.1182/blood-2017-06-788349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/28935695/pubmed" id="28935695" target="_blank">28935695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16172198">
<a name="16172198"></a>Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. <i>Endocr Relat</i>
<i>Cancer.</i> 2005;12(3):657-666. doi: 10.1677/erc.1.01025.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/16172198/pubmed" id="16172198" target="_blank">16172198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11149746">
<a name="11149746"></a>Biagi E, Rovelli A, Balduzzi A, et al. TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission. <i>Bone Marrow Transplant</i>. 2000;26(11):1260-1262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11149746/pubmed" id="11149746" target="_blank">11149746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet.</i> 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9517503">
<a name="9517503"></a>Bishop JF, Matthews JP, Young GA, et al, "Intensified Induction Chemotherapy With High Dose Cytarabine and Etoposide for Acute Myeloid Leukemia: A Review and Updated Results of the Australian Leukemia Study Group," <i>Leuk Lymphoma</i>, 1998, 28(3-4):315-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/9517503/pubmed" id="9517503" target="_blank">9517503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.<i> Biol Blood Marrow Transplant</i>. 2014;20(5):600-616. doi: 10.1016/j.bbmt.2014.01.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34570655">
<a name="34570655"></a>Burke GAA, Minard-Colin V, Aupérin A, et al. Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B-cell lymphoma: a multicenter phase II trial. <i>J Clin Oncol</i>. 2021;39(33):3716-3724. doi:10.1200/JCO.21.00920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/34570655/pubmed" id="34570655" target="_blank">34570655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16583432">
<a name="16583432"></a>Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposidein the treatment of neoplastic meningitis. <i>Cancer</i> 2006;106(9):2021-2027. doi:10.1002/cncr.21828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/16583432/pubmed" id="16583432" target="_blank">16583432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12518344">
<a name="12518344"></a>Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schvartzman E. Treatment of overt extraocular retinoblastoma. <i>Med Pediatr Oncol</i>. 2003;40(3):158-161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12518344/pubmed" id="12518344" target="_blank">12518344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2207307">
<a name="2207307"></a>Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. <i>Blood</i>. 1990;76(7):1293-1298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/2207307/pubmed" id="2207307" target="_blank">2207307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15611503">
<a name="15611503"></a>Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. <i>J Clin Oncol</i>. 2004;22(24):4881-4887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/15611503/pubmed" id="15611503" target="_blank">15611503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8443375">
<a name="8443375"></a>Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. <i>Blood</i>. 1993;81(5):1137-1145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8443375/pubmed" id="8443375" target="_blank">8443375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3297462">
<a name="3297462"></a>Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. <i>Clin Pharmacokinet.</i> 1987;12(4):223-252. doi:10.2165/00003088-198712040-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/3297462/pubmed" id="3297462" target="_blank">3297462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18338745">
<a name="18338745"></a>Coleman M, Martin P, Ruan J, et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. <i>Cancer</i>. 2008;112(10):2228-2232. doi: 10.1002/cncr.23422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/18338745/pubmed" id="18338745" target="_blank">18338745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18337441">
<a name="18337441"></a>Collier K, Schink C, Young AM, How K, Seckl M, Savage P. Case report: successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity. <i>J Oncol Pharm Pract</i>. 2008;14(1):51-55. doi: 10.1177/1078155207085355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/18337441/pubmed" id="18337441" target="_blank">18337441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21766293">
<a name="21766293"></a>Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group.<i> Cancer</i>. 2012;118(3):761-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/21766293/pubmed" id="21766293" target="_blank">21766293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17351252">
<a name="17351252"></a>Culine S, Kerbrat P, Kramar A, et al; Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP). Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). <i>Ann Oncol</i>. 2007;18(5):917-924. doi: 10.1093/annonc/mdm062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17351252/pubmed" id="17351252" target="_blank">17351252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18996004">
<a name="18996004"></a>Daw NC, Gregornik D, Rodman J, et al. Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with wilms tumour.<i> Eur J Cancer</i>. 2009;45(1):99-106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/18996004/pubmed" id="18996004" target="_blank">18996004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16595068">
<a name="16595068"></a>de Lemos ML, Hamata L, and Vu T. Leaching of diethylhexyl phthalate from polyvinyl chloride materials into etoposide intravenous solutions. <i>J Oncol Pharm Pract</i>. 2005;11(4):155-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/16595068/pubmed" id="16595068" target="_blank">16595068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11975699">
<a name="11975699"></a>Demoré B, Vigneron J, Perrin A, et al, “Leaching of Diethylhexyl Phthalate from Polyvinyl Chloride Bags into Intravenous Etoposide Solution,” <i>J Clin Pharm Ther</i>, 2002, 27(2):139-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11975699/pubmed" id="11975699" target="_blank">11975699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25542311">
<a name="25542311"></a>Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. <i>Int J Radiat Oncol Biol Phys</i>. 2015;92(1):60-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/25542311/pubmed" id="25542311" target="_blank">25542311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12802024">
<a name="12802024"></a>Diehl V, Franklin J, Pfreundschuh M, et al; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [published correction appears in <i>N Engl J Med</i>. 2005;353(7):744]. <i>N Engl J Med</i>. 2003;348(24):2386-2395. doi: 10.1056/NEJMoa022473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12802024/pubmed" id="12802024" target="_blank">12802024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3697995">
<a name="3697995"></a>D'Incalci M, Rossi C, Zucchetti M, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. <i>Cancer Res.</i> 1986;46(5):2566-2571.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/3697995/pubmed" id="3697995" target="_blank">3697995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9624235">
<a name="9624235"></a>Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. <i>Eur J Cancer</i>. 1998;34(1):33-46. doi: 10.1016/s0959-8049(97)00340-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/9624235/pubmed" id="9624235" target="_blank">9624235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21135279">
<a name="21135279"></a>Dreyer ZE, Dinndorf PA, Camitta B, et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2011;29(2):214-222.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/21135279/pubmed" id="21135279" target="_blank">21135279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25399948">
<a name="25399948"></a>Dreyer ZE, Hilden JM, Jones TL, et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). <i>Pediatr Blood Cancer</i>. 2015;62(3):419-426.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/25399948/pubmed" id="25399948" target="_blank">25399948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10713624">
<a name="10713624"></a>Duerst RE, Horan JT, Liesveld JL, et al. Allogeneic bone marrow transplantation for children with acute leukemia: Cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide. <i>Bone Marrow Transplant</i>. 2000;25(5):489-494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/10713624/pubmed" id="10713624" target="_blank">10713624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8388548">
<a name="8388548"></a>Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. <i>N Engl J Med</i>.1993;328(24):1725-1731.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8388548 /pubmed" id="8388548 " target="_blank">8388548 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20167818">
<a name="20167818"></a>Dunkel IJ, Gardner SL, Garvin JH Jr, Goldman S, Shi W, Finlay JL. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. <i>Neuro Oncol</i>. 2010;12(3):297-303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/20167818/pubmed" id="20167818" target="_blank">20167818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23574119">
<a name="23574119"></a>Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. <i>N Engl J Med</i>. 2013;368(15):1408-1416. doi: 10.1056/NEJMoa1214561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/23574119/pubmed" id="23574119" target="_blank">23574119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17652649">
<a name="17652649"></a>Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. <i>N Engl J Med</i>. 2007;357(4):340-348. doi: 10.1056/NEJMoa067749.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17652649/pubmed" id="17652649" target="_blank">17652649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33384141">
<a name="33384141"></a>Eiriksson L, Dean E, Sebastianelli A, et al. Guideline no. 408: management of gestational trophoblastic diseases. <i>J Obstet Gynaecol Can</i>. 2021;43(1):91-105.e1. doi:10.1016/j.jogc.2020.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/33384141/pubmed" id="33384141" target="_blank">33384141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19704068">
<a name="19704068"></a>Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. <i>J Clin Oncol</i>. 2009;27(27):4548-4554. doi: 10.1200/JCO.2008.19.8820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/19704068/pubmed" id="19704068" target="_blank">19704068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8611379">
<a name="8611379"></a>English MW, Lowis SP, Peng B, et al. Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis.<i> Br J Cancer.</i> 1996;73(6):776-780. doi:10.1038/bjc.1996.135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8611379/pubmed" id="8611379" target="_blank">8611379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14675675">
<a name="14675675"></a>Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. <i>Gynecol Oncol</i>. 2003;91(3):552-557. doi: 10.1016/j.ygyno.2003.08.028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/14675675/pubmed" id="14675675" target="_blank">14675675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Etoposide capsule [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; April 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Etoposide injection [prescribing information]. Eatontown, NJ: Hikma Pharmaceuticals USA Inc; August 2019</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Etoposide injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; March 2022</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strides.1">
<a name="Strides.1"></a>Etoposide injection [product monograph]. Varennes, Quebec, Canada: Strides Pharma Canada Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12149296">
<a name="12149296"></a>Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. <i>J Clin Oncol</i>. 2002;20(15):3236-3241. doi: 10.1200/JCO.2002.12.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12149296/pubmed" id="12149296" target="_blank">12149296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2997406">
<a name="2997406"></a>Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. <i>J Clin Oncol</i>. 1985;3(11):1471-1477. doi: 10.1200/JCO.1985.3.11.1471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/2997406/pubmed" id="2997406" target="_blank">2997406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17668858">
<a name="17668858"></a>Fangusaro J, Finlay J, Sposto R, et al. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. <i>Pediatr Blood Cancer</i>. 2008;50(2):312-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17668858/pubmed" id="17668858" target="_blank">17668858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22551107">
<a name="22551107"></a>Fassnacht M, Terzolo M, Allolio B, et al; FIRM-ACT study group. Combination chemotherapy in advanced adrenocortical carcinoma. <i>N Engl J Med</i>. 2012;366(23):2189-2197. doi: 10.1056/NEJMoa1200966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/22551107/pubmed" id="22551107" target="_blank">22551107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11571721">
<a name="11571721"></a>Fjällskog ML, Granber DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. <i>Cancer</i>. 2001;92(5):1101-1107. doi: 10.1002/1097-0142(20010901)92:5&lt;1101::aid-cncr1426&gt;3.0.co;2-v<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11571721/pubmed" id="11571721" target="_blank">11571721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11384092">
<a name="11384092"></a>Fleischhack G, Reif S, Hasan C, Jaehde U, Hettmer S, Bode U. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. <i>Br J Cancer</i>. 2001;84(11):1453-1459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11384092/pubmed" id="11384092" target="_blank">11384092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. <i>Semin Oncol</i>. 2006;33(1):50-67. doi: 10.1053/j.seminoncol.2005.11.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10193952">
<a name="10193952"></a>Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. <i>Cancer</i>. 1999;85(7):1599-1605.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/10193952/pubmed" id="10193952" target="_blank">10193952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25311218">
<a name="25311218"></a>Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. <i>J Clin Oncol</i>. 2014;32(32):3651-3658<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/25311218/pubmed" id="25311218" target="_blank">25311218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8699237">
<a name="8699237"></a>Fulton D, Urtasun R, and Forsyth P, “Phase II Study of Prolonged Oral Etoposide (VP-16) for Patients With Recurrent Malignant Glioma,” <i>J Neurooncol</i>, 1996, 27(2):149-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8699237/pubmed" id="8699237" target="_blank">8699237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25092781">
<a name="25092781"></a>Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. <i>J Clin Oncol</i>. 2014;32(27):3021-3032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/25092781/pubmed" id="25092781" target="_blank">25092781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17233819">
<a name="17233819"></a>García-Suárez J, Bañas H, Arribas I, De Miguel D, Pascual T, Burgaleta C. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. <i>Br J Haematol</i>. 2007;136(2):276-285. doi: 10.1111/j.1365-2141.2006.06438.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17233819/pubmed" id="17233819" target="_blank">17233819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15086738">
<a name="15086738"></a>Ghaemmaghami F, Modares M, Arab M, et al. EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV). <i>Int J Gynecol Cancer</i>. 2004;14(2):360-365. doi: 10.1111/j.1048-891X.2004.014222.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/15086738/pubmed" id="15086738" target="_blank">15086738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8622029">
<a name="8622029"></a>Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. a phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative group. <i>J Clin Oncol.</i> 1996;14(3):814-820. doi: 10.1200/JCO.1996.14.3.814<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8622029/pubmed" id="8622029" target="_blank">8622029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21902686">
<a name="21902686"></a>Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. <i>Br J Haematol</i>. 2011;155(3):366-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/21902686/pubmed" id="21902686" target="_blank">21902686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26101244">
<a name="26101244"></a>Goldman S, Bouffet E, Fisher PG, et al. Phase II trial assessing the ability of neoadjuvant chemotherapy with or without second-look surgery to eliminate measurable disease for nongerminomatous germ cell tumors: a Children's Oncology Group Study. <i>J Clin Oncol</i>. 2015;33(22):2464-2471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/26101244/pubmed" id="26101244" target="_blank">26101244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11135228">
<a name="11135228"></a>Greco FA, Burris HA 3rd, Erland JB, et al. Carcinoma of unknown primary site. <i>Cancer</i>. 2000;89(12):2655-2660.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11135228/pubmed" id="11135228" target="_blank">11135228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594313">
<a name="12594313"></a>Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for ewing's sarcoma and primitive neuroectodermal tumor of bone. <i>N Engl J Med</i>. 2003;348(8):694-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12594313/pubmed" id="12594313" target="_blank">12594313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16877720">
<a name="16877720"></a>Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study. <i>J Clin Oncol</i>. 2006;24(22):3548-3554. doi: 10.1200/JCO.2005.05.0575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/16877720/pubmed" id="16877720" target="_blank">16877720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2994705">
<a name="2994705"></a>Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PF. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. <i>Br J Cancer</i>. 1985;52(3):363-367. doi:10.1038/bjc.1985.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/2994705/pubmed" id="2994705" target="_blank">2994705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9121398">
<a name="9121398"></a>Henter JI, Arico M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. <i>Med Pediatr Oncol</i>. 1997;28(5):342-347. doi: 10.1002/(sici)1096-911x(199705)28:5&lt;342::aid-mpo3&gt;3.0.co;2-h<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/9121398/pubmed" id="9121398" target="_blank">9121398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12239144">
<a name="12239144"></a>Henter JI, Samuelsson-Horne A, Arico M, et al; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. <i>Blood</i>. 2002;100(7):2367-2373. doi: 10.1182/blood-2002-01-0172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12239144/pubmed" id="12239144" target="_blank">12239144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21967976">
<a name="21967976"></a>Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. <i>Blood</i>. 2011;118(23):6043-6049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/21967976/pubmed" id="21967976" target="_blank">21967976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3422260">
<a name="3422260"></a>Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia—an active and well-tolerated regimen. <i>J Clin Oncol.</i> 1988;6(2):213-217. doi: 10.1200/JCO.1988.6.2.213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/3422260/pubmed" id="3422260" target="_blank">3422260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3004725">
<a name="3004725"></a>Holthuis JJ, Van de Vyver FL, van Oort WJ, Verleun H, Bakaert AB, De Broe ME. Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. <i>Cancer Treat Rep</i>. 1985;69(11):1279-1282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/3004725/pubmed" id="3004725" target="_blank">3004725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280641">
<a name="30280641"></a>Horn L, Mansfield AS, Szczęsna A, et al; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. <i>N Engl J Med</i>. 2018;379(23):2220-2229. doi: 10.1056/NEJMoa1809064.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/30280641/pubmed" id="30280641" target="_blank">30280641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11821442">
<a name="11821442"></a>Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. <i>J Clin Oncol.</i> 2002;20(3):630-637. doi: 10.1200/JCO.2002.20.3.630.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11821442/pubmed" id="11821442" target="_blank">11821442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7989928">
<a name="7989928"></a>Horning SJ, Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. <i>J Clin Oncol</i>. 1994;12(12):2552-2558. doi: 10.1200/JCO.1994.12.12.2552.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/7989928/pubmed" id="7989928" target="_blank">7989928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7931470">
<a name="7931470"></a>Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. <i>J Clin Oncol</i>. 1994;12(10):2022-2034. doi: 10.1200/JCO.1994.12.10.2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/7931470/pubmed" id="7931470" target="_blank">7931470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14679119">
<a name="14679119"></a>Inoue A, Saijo Y, Kikuchi T, et al. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. <i>Ann Oncol.</i> 2004;15(1):51-54. doi:10.1093/annonc/mdh008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/14679119/pubmed" id="14679119" target="_blank">14679119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29450452">
<a name="29450452"></a>Issels RD, Lindner LH, Varweij J, et al; European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: The EORTC 62961-ESHO 95 randomized clinical trial. <i>JAMA Oncol.</i> 2018;4(4):483-492. doi: 10.1001/jamaoncol.2017.4996<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/29450452/pubmed" id="29450452" target="_blank">29450452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20434400">
<a name="20434400"></a>Issels RD, Lindner LH, Varweij J, et al; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. <i>Lancet Oncol.</i> 2010;11(6):561-570. doi: 10.1016/S1470-2045(10)70071-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/20434400/pubmed" id="20434400" target="_blank">20434400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Ann Oncol.</i> 2010;21(7):1395-1403. doi:10.1093/annonc/mdp598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8558207">
<a name="8558207"></a>Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding.<i> J Clin Oncol.</i> 1996;14(1):257-267. doi:10.1200/JCO.1996.14.1.257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8558207/pubmed" id="8558207" target="_blank">8558207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8070031">
<a name="8070031"></a>Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics.<i> Cancer Chemother Pharmacol.</i> 1994;34(suppl:S69-S75). doi:10.1007/BF00684867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8070031/pubmed" id="8070031" target="_blank">8070031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12439032">
<a name="12439032"></a>Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. <i>J Pediatr Hematol Oncol</i>. 2002;24(8):613-621.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12439032/pubmed" id="12439032" target="_blank">12439032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12078889">
<a name="12078889"></a>Kelly KM, Hutchinson RJ, Sposto R, et al; Children's Oncology Group. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group study CCG-59704. <i>Ann Oncol</i>. 2002;13(suppl 1):107-111. doi: 10.1093/annonc/13.s1.107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12078889/pubmed" id="12078889" target="_blank">12078889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21079154">
<a name="21079154"></a>Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk hodgkin lymphoma: A report from the Children's Oncology Group. <i>Blood</i>. 2011;117(9):2596-2603.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/21079154/pubmed" id="21079154" target="_blank">21079154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14739217">
<a name="14739217"></a>Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. <i>Blood</i>. 2004;103(10):3684-3688. doi: 10.1182/blood-2003-11-3911<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/14739217/pubmed" id="14739217" target="_blank">14739217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26736135">
<a name="26736135"></a>Kimakura M, Abe T, Nagahara A, et al. Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase. <i>Anticancer Drugs</i>. 2016;27(4):364-368. doi: 10.1097/CAD.0000000000000334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/26736135/pubmed" id="26736135" target="_blank">26736135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11306728">
<a name="11306728"></a>King PD and Perry MC. Hepatotoxicity of chemotherapy. <i>Oncologist</i>. 2001;6(2):162-176. doi: 10.1634/theoncologist.6-2-162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11306728/pubmed" id="11306728" target="_blank">11306728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE and Dorr RT, "Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function," <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16361627">
<a name="16361627"></a>Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. <i>J Clin Oncol</i>. 2005;23(36):9290-9294. doi:10.1200/JCO.2005.03.6616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/16361627/pubmed" id="16361627" target="_blank">16361627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17194908">
<a name="17194908"></a>Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors [published correction appears in <i>J Clin Oncol</i>. 2007;25(15):2149]. <i>J Clin Oncol</i>. 2007;25(1):85-90. doi:10.1200/JCO.2006.06.9401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17194908/pubmed" id="17194908" target="_blank">17194908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1554959">
<a name="1554959"></a>Koren G, Beatty K, Seto A, Einarson TR, Lishner M. The effects of impaired liver function on the elimination of antineoplastic agents. <i>Ann Pharmacother</i>. 1992;26(3):363-371. doi: 10.1177/106002809202600311.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/1554959/pubmed" id="1554959" target="_blank">1554959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2153766">
<a name="2153766"></a>Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: A phase II study. <i>J Clin Oncol</i>. 1990; 8(2):330-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/2153766 /pubmed" id="2153766 " target="_blank">2153766 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8448755">
<a name="8448755"></a>Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. <i>Cancer</i>. 1993;71(5):1898-1903.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8448755/pubmed" id="8448755" target="_blank">8448755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15611504">
<a name="15611504"></a>Kushner BH, Kramer K, LaQuaglia MP, et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. <i>J Clin Oncol</i>. 2004;22(24):4888-4892.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/15611504/pubmed" id="15611504" target="_blank">15611504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7595741">
<a name="7595741"></a>Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. <i>J Clin Oncol</i>. 1995;13(11):2796-2804.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/7595741/pubmed" id="7595741" target="_blank">7595741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26637720">
<a name="26637720"></a>La Rosée P. Treatment of hemophagocytic lymphohistiocytosis in adults. <i>Hematology Am Soc Hematol Educ Program</i>. 2015;2015:190-196. doi: 10.1182/asheducation-2015.1.190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/26637720/pubmed" id="26637720" target="_blank">26637720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30992265">
<a name="30992265"></a>La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. <i>Blood</i>. 2019;133(23):2465-2477. doi: 10.1182/blood.2018894618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/30992265/pubmed" id="30992265" target="_blank">30992265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21275495">
<a name="21275495"></a>Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/21275495/pubmed" id="21275495" target="_blank">21275495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19349543">
<a name="19349543"></a>Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. <i>J Clin Oncol</i>. 2009;27(15):2530-2535. doi: 10.1200/JCO.2008.20.1061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/19349543/pubmed" id="19349543" target="_blank">19349543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22868508">
<a name="22868508"></a>Lazarev I, Bogomolni L, Shani-Shrem N, Shnaider A, Ariad S, Mermershtain W. Successful treatment of mediastinal seminoma in a hemodialysis patient. <i>Onkologie</i>. 2012;35(5):275-278. doi:10.1159/000338481<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/22868508/pubmed" id="22868508" target="_blank">22868508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3524832">
<a name="3524832"></a>Lazarus HM, Creger RJ, and Diaz D, “Simple Method for the Administration of High-Dose Etoposide During Autologous Bone Marrow Transplantation,” <i>Cancer Treat Rep</i>, 1986, 70(6):819-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/3524832/pubmed" id="3524832" target="_blank">3524832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17267204">
<a name="17267204"></a>Le Deley MC, Guinebretière JM, Gentet JC, et al, “SFOP OS94: a Randomised Trial Comparing Preoperative High-Dose Methotrexate Plus Doxorubicin to High-Dose Methotrexate Plus Etoposide and Ifosfamide in Osteosarcoma Patients,” <i>Eur J Cancer</i>, 2007, 43(4):752-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17267204/pubmed" id="17267204" target="_blank">17267204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23406729">
<a name="23406729"></a>Le Treut J, Sault MC, Lena H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. <i>Ann Oncol.</i> 2013;24(6):1548-1552. doi: 10.1093/annonc/mdt009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/23406729/pubmed" id="23406729" target="_blank">23406729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12860952">
<a name="12860952"></a>Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. <i>J Clin Oncol</i>. 2003;21(14):2732-2739. doi: 10.1200/JCO.2003.01.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12860952/pubmed" id="12860952" target="_blank">12860952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25255163">
<a name="25255163"></a>Lee JW, Kang HJ, Kim S, et al. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. <i>Biol Blood Marrow Transplant</i>. 2015;21(1):190-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/25255163/pubmed" id="25255163" target="_blank">25255163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11391579">
<a name="11391579"></a>Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. <i>Cancer</i>. 2001;91(11):2010-2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11391579/pubmed" id="11391579" target="_blank">11391579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19179557">
<a name="19179557"></a>Loriot Y, Massard C, Gross-Goupil M, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. <i>Ann Oncol.</i> 2009;20(4):703-708. doi: 10.1093/annonc/mdn694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/19179557/pubmed" id="19179557" target="_blank">19179557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15863169">
<a name="15863169"></a>Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. <i>Gynecol Oncol.</i> 2005;97(2):618-623. doi: 10.1016/j.ygyno.2005.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/15863169/pubmed" id="15863169" target="_blank">15863169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22696816">
<a name="22696816"></a>Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. <i>J Reprod Med</i>. 2012;57(5-6):219-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/22696816/pubmed" id="22696816" target="_blank">22696816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20626175">
<a name="20626175"></a>Lurain JR, Singh DK, Schink JC. Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score &gt; or = 7. J <i>Reprod Med.</i> 2010;55(5-6):199-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/20626175/pubmed" id="20626175" target="_blank">20626175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17086804">
<a name="17086804"></a>Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. <i>J Reprod Med</i>. 2006;51(10):767-772.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17086804/pubmed" id="17086804" target="_blank">17086804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26508901">
<a name="26508901"></a>Marina N, Granowetter L, Grier HE, et al. Age, tumor characteristics, and treatment regimen as event predictors in Ewing: a Children's Oncology Group report. <i>Sarcoma</i>. 2015;2015:927123. doi:10.1155/2015/927123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/26508901/pubmed" id="26508901" target="_blank">26508901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27569442">
<a name="27569442"></a>Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncol</i>. 2016;17(10):1396-1408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/27569442/pubmed" id="27569442" target="_blank">27569442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8164052">
<a name="8164052"></a>Martin M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. <i>J Clin Oncol.</i> 1994;12(5):986-991. doi: 10.1200/JCO.1994.12.5.986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8164052/pubmed" id="8164052" target="_blank">8164052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324367">
<a name="26324367"></a>Masters GA, Temin S, Azzoli CG, et al; American Society of Clinical Oncology Clinical Practice. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update [published correction appears in <i>J Clin Oncol</i>. 2016;34(11):1287]. <i>J Clin Oncol</i>. 2015;33(30):3488-3515. doi: 10.1200/JCO.2015.62.1342<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/26324367/pubmed" id="26324367" target="_blank">26324367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519894">
<a name="10519894"></a>Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. <i>N Engl J Med</i>. 1999;341(16):1165-1173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/10519894/pubmed" id="10519894" target="_blank">10519894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1471649">
<a name="1471649"></a>McLeod HL and Relling MV, “Stability of Etoposide Solution for Oral Use,” <i>Am J Hosp Pharm</i>, 1992, 49(11):2784-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/1471649/pubmed" id="1471649" target="_blank">1471649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22303898">
<a name="22303898"></a>Miano M, Pistorio A, Putti MC, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. <i>Leuk Lymphoma.</i> 2012;53(9):1693-1698. doi: 10.3109/10428194.2012.663915<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/22303898/pubmed" id="22303898" target="_blank">22303898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16532434">
<a name="16532434"></a>Milano GM, Cozza R, Ilari I, et al. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience. <i>Cancer</i>. 2006;106(8):1838-1845.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/16532434/pubmed" id="16532434" target="_blank">16532434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16484584">
<a name="16484584"></a>Milligan DW, Wheatley K, Littlewood T, et al, “Fludarabine and Cytosine are Less Effective than Standard ADE Chemotherapy in High-Risk Acute Myeloid Leukemia, and Addition of G-CSF and ATRA are not Beneficial: Results of the MRC AML-HR Randomized Trial,” <i>Blood</i>, 2006, 107(12):4614-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/16484584/pubmed" id="16484584" target="_blank">16484584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7884420">
<a name="7884420"></a>Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. <i>J Clin Oncol</i>. 1995;13(3):588-595. doi: 10.1200/JCO.1995.13.3.588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/7884420/pubmed" id="7884420" target="_blank">7884420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17584910">
<a name="17584910"></a>Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group. <i>Pediatr Blood Cancer</i>. 2007;49(7):894-900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17584910/pubmed" id="17584910" target="_blank">17584910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22276299">
<a name="22276299"></a>Moccia AA, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. <i>Blood.</i> 2009;114(22), abstract 408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/22276299/pubmed" id="22276299" target="_blank">22276299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1712661">
<a name="1712661"></a>Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. <i>Cancer</i>. 1991;68(2):227-232. doi: 10.1002/1097-0142(19910715)68:2&lt;227::aid-cncr2820680202&gt;3.0.co;2-i<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/1712661/pubmed" id="1712661" target="_blank">1712661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al, “Management of Uncommon Chemotherapy-Induced Emergencies,” <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NTP.1">
<a name="NTP.1"></a>National Toxicology Program (NTP) Monograph on Developmental Effects and Pregnancy Outcomes Associated with Cancer Chemotherapy Use during Pregnancy, May 2013. Available at <a href="http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html" target="_blank">http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16541446">
<a name="16541446"></a>Navid F, Santana VM, Billups CA, et al. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: The St. Jude Children's Research Hospital experience. <i>Cancer</i>. 2006; 106(8):1846-1856.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/16541446/pubmed" id="16541446" target="_blank">16541446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10673528">
<a name="10673528"></a>Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. <i>J Clin Oncol</i>. 2000;18(4):854-859. doi: 10.1200/JCO.2000.18.4.854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/10673528/pubmed" id="10673528" target="_blank">10673528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9552027">
<a name="9552027"></a>Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. <i>J Clin Oncol</i>. 1998;16(4):1287-1293. doi: 10.1200/JCO.1998.16.4.1287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/9552027/pubmed" id="9552027" target="_blank">9552027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2983208">
<a name="2983208"></a>O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al, “Etoposide (VP-16-213): Current Status of an Active Anticancer Drug,” <i>N Engl J Med</i>, 1985, 312(11):692-700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/2983208/pubmed" id="2983208" target="_blank">2983208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27147083">
<a name="27147083"></a>Pajtler KW, Tippelt S, Siegler N, et al. Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. <i>J Neurooncol</i>. 2016;128(3):463-471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/27147083/pubmed" id="27147083" target="_blank">27147083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31454045">
<a name="31454045"></a>Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. <i>JAMA</i>. 2019;322(8):746-755. doi:10.1001/jama.2019.11642<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/31454045/pubmed" id="31454045" target="_blank">31454045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26258900">
<a name="26258900"></a>Park MJ. Durable response of leptomeningeal metastasis of breast cancer to salvage intrathecal etoposide after methotrexate: a case report and literature review. <i>Am J Case Rep.</i> 2015a;16:524-527. doi:10.12659/AJCR.894007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/26258900/pubmed" id="26258900" target="_blank">26258900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25879815">
<a name="25879815"></a>Park MJ. Prolonged response of meningeal carcinomatosis from non-small cell lung cancer to salvage intrathecal etoposide subsequent to failure of first-line methotrexate: a case report and literature review. <i>Am J Case Rep.</i> 2015b;16:224-227. doi:10.12659/AJCR.894061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/25879815/pubmed" id="25879815" target="_blank">25879815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21131038">
<a name="21131038"></a>Parker C, Waters R, Leighton C. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): An open-label randomised trial. <i>Lancet</i>. 2010;376(9757):2009-2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/21131038/pubmed" id="21131038" target="_blank">21131038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi:10.1002/pbc.27646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24 Suppl 6:vi160-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(suppl 7):vii167-vii173. doi: 10.1093/annonc/mds294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25017328">
<a name="25017328"></a>Peyrl A, Chocholous M, Azizi AA, et al. Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. <i>J Neurooncol</i>. 2014;120(1):139-145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/25017328/pubmed" id="25017328" target="_blank">25017328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8431968">
<a name="8431968"></a>Pflüger KH, Hahn M, Holz JB, et al. Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. <i>Cancer Chemother Pharmacol</i>. 1993;31(5):350-6. doi:10.1007/BF00686147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8431968/pubmed" id="8431968" target="_blank">8431968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14982884">
<a name="14982884"></a>Pfreundschuh M, Trümper L, Kloess M, et al; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. <i>Blood</i>. 2004;104(3):626-633. doi: 10.1182/blood-2003-06-2094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/14982884/pubmed" id="14982884" target="_blank">14982884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18302711">
<a name="18302711"></a>Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. <i>Br J Haematol</i>. 2008;140(6):625-634. doi: 10.1111/j.1365-2141.2007.06921.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/18302711/pubmed" id="18302711" target="_blank">18302711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14645427">
<a name="14645427"></a>Poulsen M, Rischin D, Walpole E, et al; Trans-Tasman Radiation Oncology Group. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07. <i>J Clin Oncol.</i> 2003;21(23):4371-4376. doi: 10.1200/JCO.2003.03.154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/14645427/pubmed" id="14645427" target="_blank">14645427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24290661">
<a name="24290661"></a>Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. <i>Lancet</i>. 2014;383(9927):1503-1516. doi: 10.1016/S0140-6736(13)61048-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/24290661/pubmed" id="24290661" target="_blank">24290661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9469322">
<a name="9469322"></a>Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. <i>J Clin Oncol</i>. 1998;16(2):405-410. doi: 10.1200/JCO.1998.16.2.405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/9469322/pubmed" id="9469322" target="_blank">9469322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26351333">
<a name="26351333"></a>Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians Guideline. <i>J Clin Oncol</i>. 2015;33(34):4106-4111. doi: 10.1200/JCO.2015.63.7918.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/26351333/pubmed" id="26351333" target="_blank">26351333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10857889">
<a name="10857889"></a>Saphner T, Weller EA, Tormey DC, et al. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature. <i>Am J Clin Oncol</i>. 2000;23(2):258-262. doi: 10.1097/00000421-200006000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/10857889/pubmed" id="10857889" target="_blank">10857889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9469360">
<a name="9469360"></a>Saxman SB, Finch D, Gonin R, et al, “Long-Term Follow-Up of a Phase III Study of Three Versus Four Cycles of Bleomycin, Etoposide, and Cisplatin in Favorable-Prognosis Germ-Cell Tumors: The Indian University Experience,” <i>J Clin Oncol</i>, 1998, 16(2):702-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/9469360/pubmed" id="9469360" target="_blank">9469360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8352235">
<a name="8352235"></a>Schiller G, Lee M, Territo M, Gajewski J, Nimer S. Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. <i>Am J Hematol.</i> 1993;43(3):195-199. doi: 10.1002/ajh.2830430307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8352235/pubmed" id="8352235" target="_blank">8352235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20660290">
<a name="20660290"></a>Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. <i>Blood</i>. 2010;116(18):3418-3425. doi: 10.1182/blood-2010-02-270785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/20660290/pubmed" id="20660290" target="_blank">20660290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19584400">
<a name="19584400"></a>Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i>. 2009;114(10):2051-2059.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/19584400/pubmed" id="19584400" target="_blank">19584400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11857004">
<a name="11857004"></a>Siderov J, Prasad P, De Boer R, Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. <i>Br J Cancer</i>. 2002;86(1):12-13. doi: 10.1038/sj.bjc.6600003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11857004/pubmed" id="11857004" target="_blank">11857004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17279006">
<a name="17279006"></a>Simon T, Längler A, Berthold F, et al. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: Results of a phase 2 trial. <i>J Pediatr Hematol Oncol</i>. 2007b;29(2):101-106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17279006/pubmed" id="17279006" target="_blank">17279006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17479288">
<a name="17479288"></a>Simon T, Längler A, Harnischmacher U, et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. <i>J Cancer Res Clin Oncol</i>. 2007a;133(9):653-661.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17479288/pubmed" id="17479288" target="_blank">17479288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11697833">
<a name="11697833"></a>Skarlos DV, Samantas E, Briassoulis E, et al, “Randomized Comparison of Early Versus Late Hyperfractionated Thoracic Irradiation Concurrently With Chemotherapy in Limited Disease Small-Cell Lung Cancer: A Randomized Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG),” <i>Ann Oncol</i>, 2001, 12(9):1231-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11697833/pubmed" id="11697833" target="_blank">11697833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8219241">
<a name="8219241"></a>Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. <i>Blood</i>. 1993;82(9):2920-2928.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8219241/pubmed" id="8219241" target="_blank">8219241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19720897">
<a name="19720897"></a>Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. <i>J Clin Oncol</i>. 2009;27(28):4787-4792. doi: 10.1200/JCO.2009.23.1548.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/19720897/pubmed" id="19720897" target="_blank">19720897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11319295">
<a name="11319295"></a>Sprinz E, Caldas AP, Mans Dr, et al. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. <i>Am J Clin Oncol.</i> 2001;24(2):177-184. doi: 10.1097/00000421-200104000-00016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11319295/pubmed" id="11319295" target="_blank">11319295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12488411">
<a name="12488411"></a>Sundstrom S, Bremnes RM, Kaasa S, et al; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. <i>J Clin Oncol</i>. 2002;20(24):4665-4672. doi: 10.1200/JCO.2002.12.111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12488411/pubmed" id="12488411" target="_blank">12488411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17914077">
<a name="17914077"></a>Superfin D, Iannucci AA, and Davies AM, "Commentary: Oncologic Drugs in Patients With Organ Dysfunction: A Summary," <i>Oncologist</i>, 2007, 12(9):1070-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17914077/pubmed" id="17914077" target="_blank">17914077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9027788">
<a name="9027788"></a>Suzuki S, Koide M, Sakamoto S, Matsuo T. Pharmacokinetics of carboplatin and etoposide in a haemodialysis patient with Merkel-cell carcinoma. <i>Nephrol Dial Transplant.</i> 1997;12(1):137-140. doi:10.1093/ndt/12.1.137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/9027788/pubmed" id="9027788" target="_blank">9027788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12118018">
<a name="12118018"></a>Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent verses sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. <i>J Clin Oncol.</i> 2002;20(14):3054-3060. doi: 10.1200/JCO.2002.12.071<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12118018/pubmed" id="12118018" target="_blank">12118018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18758316">
<a name="18758316"></a>Takezawa K, Okamoto I, Fukuoka M, Nakagawa K. Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. <i>J Thorac Oncol.</i> 2008;3(9):1073-5. doi:10.1097/JTO.0b013e318183af89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/18758316/pubmed" id="18758316" target="_blank">18758316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12697884">
<a name="12697884"></a>Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study. <i>J Clin Oncol</i>. 2003;21(8):1581-1591.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12697884/pubmed" id="12697884" target="_blank">12697884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32845001">
<a name="32845001"></a>Tomizawa D, Miyamura T, Imamura T, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. <i>Blood</i>. 2020;136(16):1813-1823. doi:10.1182/blood.2019004741<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/32845001/pubmed" id="32845001" target="_blank">32845001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Toposar (etoposide injection) [prescribing information]. Irvine, CA: Teva; April 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9920950">
<a name="9920950"></a>Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. <i>N Engl J Med</i>. 1999;340(4):265-271. doi: 10.1056/NEJM199901283400403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/9920950/pubmed" id="9920950" target="_blank">9920950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet.</i> 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15503297">
<a name="15503297"></a>Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. <i>Pediatr Blood Cancer</i>. 2005;44(4):338-347. doi: 10.1002/pbc.20227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/15503297/pubmed" id="15503297" target="_blank">15503297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8201379">
<a name="8201379"></a>Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. <i>J Clin Oncol</i>. 1994;12(6):1169-1176. doi: 10.1200/JCO.1994.12.6.1169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8201379/pubmed" id="8201379" target="_blank">8201379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cediton.1">
<a name="Cediton.1"></a>Vepesid (etoposide capsule) [product monograph]. Mississauga, Ontario, Canada: Cediton Pharmaceuticals Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18453518">
<a name="18453518"></a>Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). <i>Ann Oncol</i>. 2008;19(9):1578-1583. doi: 10.1093/annonc/mdn181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/18453518/pubmed" id="18453518" target="_blank">18453518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12556954">
<a name="12556954"></a>Watanabe R, Takiguchi Y, Moriya T, et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. <i>Br J Cancer.</i> 2003;88(1):25-30. doi:10.1038/sj.bjc.6600687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12556954/pubmed" id="12556954" target="_blank">12556954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34587368">
<a name="34587368"></a>Watari N, Yamaguchi K, Masuda T, et al. Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: Two case reports. <i>Thorac Cancer.</i> 2021;12(21):2956-2960. doi:10.1111/1759-7714.14166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/34587368/pubmed" id="34587368" target="_blank">34587368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7989929">
<a name="7989929"></a>Weaver CH, Petersen FB, Appelbaum FR, et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. <i>J Clin Oncol</i>. 1994;12(12):2559-2566. doi: 10.1200/JCO.1994.12.12.2559.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/7989929/pubmed" id="7989929" target="_blank">7989929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17151191">
<a name="17151191"></a>Wen Z, Tallman MN, Ali SY, Smith PC. UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. <i>Drug Metab Dispos</i>. 2007;35(3):371-380. doi:10.1124/dmd.106.012732<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/17151191/pubmed" id="17151191" target="_blank">17151191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7512129">
<a name="7512129"></a>Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. <i>J Clin Oncol</i>. 1994;12(4):701-706. doi: 10.1200/JCO.1994.12.4.701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/7512129/pubmed" id="7512129" target="_blank">7512129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15581952">
<a name="15581952"></a>Williams SD, Kauderer J, Burnett AF, Lentz SS, Aghajanian C, Armstrong DK. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. <i>Gynecol Oncol.</i> 2004;95(3):496-499. doi: 10.1016/j.ygyno.2004.07.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/15581952/pubmed" id="15581952" target="_blank">15581952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11929754">
<a name="11929754"></a>Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. <i>Blood</i>. 2002;99(8):2685-2693. doi:10.1182/blood.v99.8.2685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/11929754/pubmed" id="11929754" target="_blank">11929754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8652810">
<a name="8652810"></a>Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996;87(12):4979-4989.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/8652810/pubmed" id="8652810" target="_blank">8652810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19512958">
<a name="19512958"></a>Yang J, Bogni A, Schuetz EG, “Etoposide Pathway,” <i>Pharmacogenet Genomics</i>, 2009, 19(7):552-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/19512958/pubmed" id="19512958" target="_blank">19512958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12942558">
<a name="12942558"></a>Yoh K, Goto K, Ishii G, et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. <i>Cancer.</i> 2003;98(5):926-931. doi: 10.1002/cncr.11606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/12942558/pubmed" id="12942558" target="_blank">12942558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10068272">
<a name="10068272"></a>Zander AR, Berger C, Kröger N, et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. <i>Clin Cancer Res</i>. 1997;3(12 Pt 2):2671-2675.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etoposide-drug-information/abstract-text/10068272/pubmed" id="10068272" target="_blank">10068272</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8430 Version 395.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
